-------
-
' C-
O)
(0
Ol
1
in
CO
H
D
g
S
,,.
X
1
S
<£)
^*
o
i-t
O)
EH
1
e: 09/03/98
e:
4-> 4-)
ro ra
Q Q
S: 0
a
4-> 0)
n a:
o
<±£
.-
^_-
g
•H
H
O
N
(0
•H
5
O
a
•H
I
sT
OJ
1
H
• 4-1
I
JN
<«*
0
O
r-4
•3'
U
3
s
o
c
•H
hylisothiazol
1
s
OJ
o
d
di
n
o .
, w .
- c
0
4J
4-> CO
o> 'E -a
W -H O
s j a -
T3
0)
to O
C .-1
O *H
•H ra
4-> CO
4J "a
"s
•H
a
ra
a -o
O 0)
U 0
1— 1
1— I
1 4-) 4-J '
a) c c
Oi Cd M
• M "to
c ty >
•H 4-> ra
< .— ra
— "D < 0)
-^- 0) ^x >
0) O 0)
CO C CO
O -H
QMS
w ^ a CD
. 0) 0) O »H
ro c w o >i
E 3 O-*-. O
co ty ij
aw ra
' Cu ro ty
< a: >i
-*x
=3: •
x a CD
• ro O ^H
X S ^' O
ffl CJ >i
SsJ^ U
-I • • 03
o o) ra o
CO E-< 2 Q
• W "D —~'
^-t < cy cy
a— 4J co
a o -H
s-C 0) C 3:
4-J i^
. ra w CD '
x a: w x:
ro ot 4->
c
3
1
C
•H 0) cy
CLM 4J CO
££°|
• CO t/3 0)
c AJ co ^:
'E a: M o
en '
t-4 1
O fij '— ^
Iu O >,
iij 'c
V-t 0
US (0
C 1 ">,O
O *-( ^
-H CO.
4J 4-) O -H
me e
U 0) rH -H
•H E nj 4J
on Type, Appl
ication Equip
(Antimicrobi
ng Factor (An
•H rH 0) -H
jj a a o
ro a >i c
o < s* o
•H D
rH ^ CO rH
a c ra c
,3; -H t-i fH
Cd -H 3 >,
H £-• CO O
M
CO
'
. g
M
1'
(X
fH."
CO —
M 4-1
S c
cc o
ta o
OS — ; ;
a: Q
Sea
u
Eu
W 1
»J 2
O3 O
w 2
e? -v.
M Q
J O
^ g
1 §.
^^
jj
"c
o
0
Q
O
s
0
• g
o
a
&
t— i
cL
o
O)
CO
4->
c
o
o
IN/LATEX/POLY
CO
OS
CO
0
CO
§
,3. , ,3. ^, _ ^,
CM CM CM ..CM '
CJ CJ ' O CJ
O O O O CJ . O ' '
1
CO CO CO CO CO CO
z z z z z z
CO CO CO CO ' CO ' CO'
2 Z Z Z Z Z
CO CO CO CO CO CO <
Z Z Z Z Z Z t-t
£-<
CO
Q
z
CO CO CO CO CO CO M
a z z z z z
Q
o
; j S
E:
0
2
CO CO CO CO CO CO U
•Z Z Z Z Z -Z IH
o
CO , CO. CO CO CO • CO ff.
a
* * * * * * . g
m oo CM CM ' CM ' CM
• ^ rH tH V-i Q)
ro m ' co
S 3: -3 S E>
n -
3 S S S _ S S -
O O U O O O
CO CO CO CO CO CO
CO
EH
CO
>•;
CO
t3
a:
Cd
." o
• ' • ,8
, h-l
o
CU
'./ '. • ' i
•^r
' •
CO
o
< -
CO
CO
"Z.
CO
•z.
z
'' . •
,
i '.
w
* '
• - !
1-1
m
n
m
s
-q
\
o
CO
I-H
S3
to-ro
>i O
(0 -H
rH
c a
•H <
t '{recirculat
n label, Not
for this use
COO)
cy -H
H -H S*
CJ XJ
(H C O
T
CM
CJ
CM
O
CO
CO
Z
•CO
"Z. -
CO
E:
1
^
*
in
n
oo'
r-H
S
J •
\. ,
o
CO
S-t
o
E 0)
Q> C fH
4-> O J2
co ra
>i4J 0
CO O -H
c - a
•H — ro
b {recirculat
slug) (initial
iicable, Not
c —' a
CD 4J O
g ^JJ- ^
0) 0). 0) CO
ra c ra .c
•i u
CO --H
c c a
•H i (0 £
CO — ) 4J
coo'
t (recirculat
Itenance, Not
c applicable
C -H O
CO C •-<
of °
0) CO rH
(0 3 CU
-------
to
s
*
I
*H
to
1
86
s
<
x
1
<
f
O
I
l-
1
s»
O >i
Z a ol^ o
n ol u
gi> a
ro o
*x
x ao
x S 275
3 ° **
^ • • a
-* X X B
O O (5 O
o> f za
^"•0 —
«s^l
xS nl
S ^ ^
c
i
c
• 3 T3 —
-1 S SI
Q.M J-> e]
S"£g g
c -u n .c
so:-< o
(0
I 1
O 0 —
U* U >i
U4 C
u-i o
to
13 tO
§ lss
-1 CO
4J U O •*-«
ra c E
O © «-* -H
•H g 0 JJ
>-t 5.-H C
C«3 O J-<
s -HO
1) C £ U
CU O -^ O
?I> C tu
ro <
§O^ &
•H C
•H -H 0 *H
jj aau
SO. >i C
*£ E- CJ
r-t - S» H
(X c m c
€ M
Cd -H 3 >i
E- t- CO O
M
CO
2
O
tH
CO —
Id C
CS O
to o
oZ o
1 §
M 2
o -^
M O
tt3 O
21
2
S ' i
CM
O
CO
U
CO
CO
CO
2
CO
2
g
1
2
0
2
X %
8
Q
2
IH CO
•z
a
3 *
o
U
r-
0
s >
^r
en
>
^
td O
> to
H
O T3 CD
fl* QJ -Q
«-« m
o: o
U CO -H
< o 'a
E -H
O_ -U aJ
E-. o 2 W
SO 3
..
2 cSS
&3 ro c o .
O 0 .-H
J Ij-C-H
w o! Il §"
U Q) C -U
p tJ -H O
CM CM O-J CM CM
CJ ' U CJ ,CJ O
O CO O CO CO
< CJ < U U
CO CO CO CO CO
CO CO CO CO CO
222 22
CO CO CO CO CO
222 22
CO CO CO CO CO
222 22
CO CO CO CO CO
222 22
CO CO CO CO CO
222 22
* * * * *
r- o CM CM _r-
> > > > >
m m r- r- , ^
CO' tO rH rH CO
> > > > >
j J >J _3 J
O O U U O
CO « CO CO CO"
"O OJ Q)
a> 3 3
CO C CO
CO -H QJ -P -H
O -P J-> 2 J->
3 JJ .H
•H 2 o M -H" o.
C * JJ J3
O «— 1 CD C (Q <1)
J3 XI XI
^ >-t O 4-^00
C-H C-H
E o a E o a
0) O 0) - .
4J O 4-» rH O
-2 (0 2
0) -- fl> ^H
•H C C i— t
> o* (a > — ro
W XJ •— 1 W 3 <— 1
0) 3 tt > >
m in r~
CO 00 ^
> > >
j j j
CO CO CO
Q)
'•U D
c Z m
w -
•H J3 a)
u y-t
H ~ 0
CO 3 ~H
01 ~H Q,
S S
O O '
O) O
0 S
CO CO
2 2
CO CO
. CO CO
2 2
CO " CO
2 2
% %
CO CO
2 2
•* •*
i-l
r-
CJ
h3 J
0 0
CO CO
4-J (H
2 OJ
O
la .
(0 (0
o o
0 2
CO -
o - >
^ ^
(O
rH
> >
J »J
CO CO
-------
;
' '
Cft
Q>
en i
ro
Oi •
I
tH
m
CO
M
D
J
§
•H
H
O
•H
JC
O
a
i
ffi
en
rt iH
2 i*
eg -P
K
1 JJ JJ
arc c
a: Ed M
• rJ. CO
c
'•£ % £
S C |D
M ^
«; -- ro
4J — "V,
GOO)
en c ca
0 -H
Q CO S
CO rJ Q«
S 3 0\ 0
CO CD r4
O.JJ ro
Q, ro (D
ct; cc >i
*: •
x a. CD
* CO O «H
X S -J 0
ro CJ >,
S C2)I^ 0
rH - - CU
•H X~ X W
O-O) ra O
CO EH S Q
• M TJ •—
rH < 0) CD
a. — jj to
a. O-H
.< a) C S
• ro to ,
' **H C
*H O
U) CO
plication Type, Application
3, Application Equipment —
^e Type (Antimicrobial only)
fluencing Factor (Antimicrobi
D* C rcj C
<.H<£,H
Cd -H 3 >i
EH EH CO CJ
CO
'
,
[GIBLE FOR REREGISTRATION
VNON-FEED {conM:}
Cd ^ O
CO 1
Cd 2
CO O
ID 2
CM
O
CO
r-1
CJ
,.
CO
§
CO
s
CO
< CO
M 2
cc
£H
D
Q
2
IH CO
a z.
i
2
CJ CO
n 2:
£-4
<
i 3
o
< CO
a
3 , +
o
rH '
to n
D
S
-- s :
j
o
CO
,
E 0)
:HANGER WATER SYSTEMS
ceatment (recirculating syste
, Not on -label, Not Applicabl
Licable for this use .- J
X J-» -H CL
. Ed ro &
±4 -H CD
EH CU JJ
Cd tO C O
CM
CJ
CO
<->
K
CO
§
CO
CO
CO ".
2
CO
2
CO
2
2
CO
r*
' S
m
rH .
S
j
• CJ
CO'
JJ
o
— to
E - 3
reatment (recirculating syste
=nt/maintenance, Not on label
:>le, Not applicable for this
Water t]
Subseque
Applic at
-*
CM
CJ
^
CO
. • rH
0
t
CO
CO
< CO
f£
.EH
CO
Q
2-
rH CO
Q
O
o
En
1
2
S
CJ CO
M 2
ri
S
•* g
a
3 *
O
• m
Q)
to m .
D
m
>
*3
3
jj r
O 0)
* CO
CAL PROCESSING WATER
itive treatment, Not on label
L, Not Applicable, Not applic
s use . \'
CC > 0) -H
co o> ro JJ
O CO rH
Q CU i~t
2 M c O
IH CU O
-------
o
e
a*
1
,
09
§
• " I
3
M
2
g
•H
I
H 1
K r-\
ft £
2
|< T
1 i
^
r* o
o i
1 7
t- g
1 3
o
i 5
x o
. § 3
S3 S
' S *•
9 h CM
a: o 01
D. 0
SIS
0 9
ll 3
c
o
jj
13
AJ w
O B T>
" "j °
= u
•a
g|
O -H
-4 ra
u «
jj Q
E
Q
a
13 13
O 0
U >
1 JJ U
e) c c
K U M
• u *w
C 0 >,
— 4 AJ 13
s c-o
M —
5 - ra
ris^
e> o ffi
w c w
B 01 'S
01 w ao
• 0 O O-(
X-4.C W O
IB C i> O >1
s 3 oK o
n olu
G.AJ (0
£u ra e>
^
X Q. O
• 10 O-<
~4 • • 0
•H X X W
" M T) —
•H < (U ®
Q. — iJ (0
a o-i
• a a a
x a: n.c
tq O w
SB -10
c
c
• 3 13 ~
*H fl» O
«; — c g
C JJ W.C
•~t ra ai AJ
S a:-) o
"s
o ra ^.
^Cu O >»
«w o
O >-4 M
-H C U
4J AJ O -H
S ?^ B
O Cl f-t -H
-H E 0 JJ
-i a-< c
O.-H A <
a? c E °
ao-H u
&3|S
ra <
c o — o>
O —4 C
-H •-* fl» -H
il Q.Q. O
utzt- a
•-4 •. O »H
O.CC<2 c
CO -H 3 >i
f- t< 05 O
(O
o
(-1
H
0 .
05 —
O
§ g
Id- O
&. —
C£ O
Q W
E g
J Z
S §
i |
CO 1
CO O
CM CM CM
O O U
CO ^* ^" CO CO M" ^* . •
r-H CM CM t-H r-t CM ' CM
O O U U U CJ O
O CO CO O O * CO CO
m T-C »M m n .-H rH
< CJ 0 < < 0 0
CO CO CO CO CO CO CO
— ZZ Z. X Z -Z. 22'
JJ
c
oca co co co co co co
"~"
r- ' « - p-
^ S S S 3= 3 S
n en - co ri m en co
rH ' iTl tH -CO
* n tH • • ro •
S S S S 3 S S
•j j j ^
o o o o u , cj a
CO CO • CO CO CO CO CO
4-1
o - ^
(U 2 -CO 0 (D O 0) 0)
CO M-H K) WOMO
3 - (D.C 3 JJ3C3C
GJ Xi -u o ra TO
-- COO^H ra to 2WCJJWC
O -Q a> 4J g JJ^H
pf] 3(-HO O 4J(QQ> 4JCQJ CQiQJ C J3
^ C flj (U (Q2Q) raQi E C 03 E J-> (Q OHO*CO CT -H QJ
^-I^HO -H W -H,Q, l-lOO J-lOO OJOJO O^M
M ooa. CCOT cjj COG. c-a. sea. 3<—C (UC^H H 0)O*H OlfOi-H
ts; jJCTra aJtora JJQ. jj — ra "EJJ —* ra jj jj co •*-> ra
E- o)O co a — o — 01 rao co
CO S4(0*H i-i (D -H W < S-t CTi-H IHD^-H S-< E -H in O -H
O (D X» -* (!) Q.-H <1> 013^-t (UDf-i OJO--) 0) •-(
2 racocx ra-Hd. n3Ow ratoc^ratocx ra3D< raoo.
M 3 — rt; S*Ora 323 3 "— <; S — * rt, Srt,<; 32(0
CM
0
•«• . • co
CM ^H : -
u , o
CO CO
u - §•, '
CO CO *
2 2
CO CO
2 2:
CO rt| CO
2 S z
EH
CO
Q
2
CO M CO '
. Q
1
o
CO O CO
2 I-H 2
s
O!
co < co
2 2
a
* 3 *
s • '
CO i-t . . *•
0)
.H w n
3 S
01
en to
3 3:
M.'
CJ* O
CO CO
.
QJ f-H
JJ XI
CO (3
CO -H
o>a
S JJ CU
td ra JJ co
6-t •-) O D "
CO 3 2 "
x o to
CO J-i -«-l
CD O
M M ra J-i
CQ — ^H O
CQ
-------
z
CD
CT
ra
a*
i
in
CO ' .
HD
_:
0
s
•a; i
X ~
. H
W ^H
-, -Oi o
H
n
r- O
o 8
i-H X
CJ
QJ
H C
O
i 5
^ "g
i Date: 05/03/91
: Date:
[Methylisothia:
3l-i CNJ
0:0 . o*
a o
jj QJ m
J-t at
QJ a: nt
OS CU U
c
o . •
4J
. (0
JJ CO
•H QJ
Q) E -a
CO «H O
D J 0 '
- TJ
CD
WO-.'
O -H
-H (0
JJ CO
TO -r4.
,4J Q
-H
E
•H
O
•H
.C
Q •
(0
i-i
O 73
O QJ
" QJ £
i— t
,— 1 '
1 JJ JJ
QJ C C
OS Cd l-t
• ^ "n
C QJ >.
•H jj nj •
S C T3
i— ( • M
< — (0
— -o < CD
— Q) •*-. >
JJ — -s.
QJ O Q)
'CO C CO
O -H
Q co 5
CO H O. OJ
• QJ 0) O i-H
X 'H £ Ui O
TO C J-> O >.
S 3 O \ O
CUJJ (0
o. ra QJ
• x a QJ
• CO 0 -H ,
-m o >,
S o|-*v O
^ '• • a>
•H X X 03
o QJ ro o
CO E- £1 Q
•H < QJ QJ
Q,— JJ CO
a o -H
fiC 0) C S
JJ J4
• HJ CO QJ
X CC CO .C
(13 Q) JJ
C
3
1
C
D,M JJ. CO
Curt^ O --H
• QJ CO QJ
C JJ « .C
•H (0 Q) JJ
£ OS-H 0
CO
g.
O fO —
fa U >,
. -H r-j
U-) C
n-i o
^0 (0
•H
C >i O
O t— 1 i-i
•H CO
JJ JJ O -H-
(0 C E
O 0) M -H
•H E (0 JJ
•H U.-H C
CU-H XI rf.
Lcation Type, AI
Application Eqi
Type (Antimicrt
jencing Factor
•-1 - QJ i-t
a o> otw
a, c ro c
az -H •w M
M5S->.
EH E-« CO O
M
CO
;
2
O
E-1
Q£ O
Id 0
EC —
gtd
Ed
Cu
S I
CO O
5 5
M O
td ' O
CO 1
Ed JS
CO O
,
4J
C
0
<
t~*
CO
D
Q
2
M
0
o
g
1
2
o
2
O
M
fC
D
§"
a
o
CD
" QJ
CO
. JJ
c
o
0
s.
Cd
^ SCRUBBING SYS1
tr;
INDUS
CJ
CO
0
^
CO
o
<
CO
2
CO
CO
s
CO
CO
CO
2 . ,
CO
r—
s
en .
i-i
B
hj
CJ
CO
4J
O
».2 QJ
E ^ 3
0) ^H
jj a) to
CO XI -H
> (0 .C
CO •-{ JJ
t? C J-t
COO
4J JJ
ro o QJ
Jtment (recircu]
i/maintenance, ^
5, Not applicab]
QJ C -H
tj QJ xi
JJ 3 (O
CT 0
,(4 QJ -H
QJ « M ,
S CO <
0 ' , ' " '
•V " •«• CO" -CT ^ -«T •<3''-3'- -W
CM CM ' i-l , CM. 'CM, CM- CMCM CM
CJ O *CJ O CJCJ O'O CJ,
--'*. •. •. *.'«.!- ^^' *.
CO CO CO COCTt'CO'CO -'COCM-C'CO.
«-H 'i-H. O i-ICMi-Hr-l t-HCMCMi-H
O CJ < UCJ.O.CJ OCJCJO
CO CO CO COCOCOCO .COCOCOCO
2 2 2 2222 2 .-2 , 2 2
y - '
co co "co-cococo'co cococo ~co
2 2- 2 2222 2222
CO CO ,'COv, CO'COCO CO' CO CO CO CO
2 2 2; 2222 "2222
CO CO CO •COCOCOCO COCOCOCO
22' 2 2_222 2i222
Q • . '
I
2 '
CO CO ' CO CO CO CO', CO CO CO CO CO
g2 2 2 • ' 2-22 ' 2 • 22^22
O ' •
Q - '
2
I-HCO CO' CO, COCOCOCO CO'COCOCO
_2 2 2 2222 2222,
a
3*-'-k -K -4i-)c'-K^( ^c^c^c^i
O " '
i-i - ,
CJ' i-H ' P- CM CMT-4CJ -^TTfO'CX]
W . CD-. •^•" -W ^3" -^* ' S-SCO •
>.->••>> s - s ' s
*H i-i ' P- P-- ' oo • p~p-mcn
- • ... -•.••o
•^3* rH i— i i— 1 i— 1 i— 1 i— I fl *
o o
J ' J ^ j ^ ' j j • K). j -j *4 :
O, CJ O 'CJOCJCJ CJCJCJO'
CO CO COvCOCOCOCO COCOCOCO
C . C t-i ' O
•H QJ QJ -H O C *l-l
s-i co n j-j 4-t o '
3.33-0)-- O
Q 4J QJ •• JJ .H . ' ,-|
CO JJC00^ * ' O XI QJ
-•H O-HSXI 2ro -xiJJ
JJj=-2£ ffl O -roO
CjJ-*.4J-^Of, ^-H. r-J2
QJ >H <« >H *H • r- 1 f)
E-u^-ttoj-j^rai-f- fd£X- c-
JJOO-HCO. -HJi , -HQ, > OQ)
ra 2 '.*M aJajtwjjCi, jjnj •— i
CO CU -H £ -H OJ -r-f JJ XI
os-i«ac(Xcu-c ' ,^cjj ora
O QJ' XJ 3 XJ 0 2 ^ -H
i-l(OOJJQJCJjJ I ,'-jJ*. JJCLCO
-H i-l -H C -H C -' CO) C CL 3
OJJi— lOJC^rHOJCJ QJ •— 1 QJrt!
srocaEc, a'E-i ' EXJ EW
M>-OQ.iJ-HOJJJX3 ,.. JJfO JJJJ^H
E-'Mnjnjioronj'nj coo ro o £
E-*QJJJ QJCCJO QJ-H QJ2JJ
BCOOJJt-lQJjJiJ.H Ur-11 ^
QJ2OJJO.O4J'H ,-JJfX-' 4J - * M
tl 2 W 2, - Q, tX CLO
OCX- O)-^ QJC1 > Q)fiC QJE^-l
2 0)->TI->< ,,>W*' >3
idnj^i-ijJOf-tjjjj JJQ ' jj^c
CC-i-tJJXl<0-rHXlCOOCJ ' C02CJ " 'fOD*Xl
O(-tGnj>JJnJ>2co >co >C(0
SJJtOOM(OOlJ3 U-D H-^'O
tJCOM-l.-HOJE-HOJ^ QJ^H QJi-l-rt
(3,33'H CO O •— t COQjCO COQJCO v CQQJi—J
E-*"OCC1.QJJJD.QJE'H CJXl-H CUJJQ.
,g cnjD.'^g&.sj'-pi: • s^(0£. .-^Qja.
SME^QjrtjfiqaiCijj • QJ fH -u QiSfO
en
r--
-------
V
f*
,.
f"
at
'
.
03
3
3
i
X
i
S.
<3>
o
g
1
e>
o o
22
I"
^> &
Si:
I
•rt
O
H
n
s
•g
-H
1
I
m
|
T
N
o
rH
r>
o
«
O
*3
°
I
g
*ri
rt
O
M
IS
O
a
•H
1
I
CM
01
O
n
a
e
3
c
o
JJ
13
u «
e a •o
H) -4 O
S JO
s
K O
C ~H
O -H
•H BJ
u n
« «H
JJ 0
J
j:
0
tl
1-
1 JJ JJ
a c c
ttU 1-1
c a ><
3 CT|
M H
< — 10
— '°* >,
(U O 'S
n c w
S» J
n ti o. o>
xSSBTj
ra c JJ u >i
S 3 Oi*^ O
« art u
C.4J fij
«3 >,
X Q. O
|S^
X ra4"s» o.
-H • • Q)
•H X X OT
o at <3 o
WE- 2E CJ
«H <
K OS B) £
*C °
3
,
• 3 TJ — •
*— 1 Q> 2J
*Sif
- ey w €)
C *J W.C
-H (3 03 J->
¥
u t
£ |5
U-l C
IM O
^
U) (0
^
c I >lo
O -4 U
•H CO
<0 C S
o e-i-H
-4 g KJ iJ
&^"o —
fl 0 K
- -1 O
a c K u
ao -H u
t* JJ C Cw
a <
C 0— 0>
O-H C
ZJ'aa.'d
-< 3
o. c sa c
roll*
fr< f to O
M
U
•z.
o
E-
M „
M .U
[O C
a: o
r,1 Q
CC —
Ctf Q
o u
tu CJ
tu
Ct] 1
t-i 2
M Q
ta o
CO 1
td 3:
CO O
O 2
T
0
CO
rH
U
CO
CO
2
CO
Jj
~{Z
o
O CO
— 2
a
i
z
o
CO
cc 2:
Q
2
t-H CO
2
a
3 *
o
CM
O r-
co
s
o
s
J
—
CJ
CO
JJ
O 0)
J3
- ra
-H O
— CO -H
(0 a
C M Q.
O fQ
o c
— o -u
0
CO 4J 2
Q 0
&y 4-> J3
c ra
O QJ O
2 e-H
M JJ rH.
H Q) Q,
3 M <
CJ JJ
O "o-H
tJ a (Q JJ
S Cu O
>
-3
O
CO
JJ
o
CD
.H
O (0
•H O
4J -H
CO .-C
E a
o a
3 w
JJ fl) CO
C O •> 3
CU C JJ
E ra c co
JJ C 0) -H
n Jcr o
a "w "ra
Q) <1) 0) -H
W M d-H
cu co TJ ro
-T
CM
o
CO
CJ
CO
2
CO
2:
CO
§
CO
CO
2
CM
n
>•
tH
r-
>
J
O
CO
CO
-»-H
ax:
E J-)
a
o
c
-H 0)
t) <-t
OJ.0
JJ tO
(U CJ
jj a> a
C O fO
a> c
E ra JJ
JJ C O
n c -
ra .-i
a> E .a
•H JJ O
> 3*0.
<
CO CO
CU CO 2 3
, CM
O
•*r •&
CM rH CM
, O CJ CJ
co n co co
tH CM O iH
0 , CJ . < 0
7
CO CO CO CO
CO CO CO CO
CO CO CO CO
CO CO CO CO
2: 2 2 2
CO CO CO CO
2 2 Z • Z
CO CO CO CO
2222
CM CM r- CJ
>• > >
03 CO
CJ
O CJ CJ CJ
CO CO CO CO
JJ
o
CO
•* 3
0) CO
ra .c
c n
o o
1-1
JJ
O 0)
~ - CO
c P.-H
0) C -H
E ra CL
-u c a
to C JJ
JJ -H O
•H JJ QJ
(0 Q) .Q
^ cru
O Q) -H
S co§*
•^ -T -^r
CM CM CM
CJ CJ CJ
CO CM CO T
«H CM tH CM
CJ O CJ U
CO CO CO ' CO
CO CO CO CO
2222;
CO CO CO CO fC
2 2 2 2 w
05
CO
Q
CO CO CO CO M
Q
0
£
I
2
0
CO CO CO CO O
i=C
CO CO CO CO <
2222'
a
o
m CM CM n
r- - « . 0)
S S 3
K.,.
CO CO CO *
s s s s
u o o u
CO CO CO CO
CO
M
t,
OS
o
CO
C5
2
I-H
a;
. Q .
u
o
a
M
o
T
»,CM
ccT
i-H
O
§
CO
2
CO
CO
CO
CO
2;
o
rH
>
J
s
CO
w
3
C CO
JJ O .C
'E *. JH
0) Q) >W
c ra cy.
«. c ra
JJ O U
C -H
JJJ -H
CO 3 *H
M oi a
-------
1
m
iH
OJ
en
ro
CU
i
tH
CO
M
i-J
E4
2
.
' •*
X
H
§
S
."• Si
r-
o
i-H
E
•H
EH
1
CO
CTl
-s.
CO
o
en
0
Q> Q)
JJ JJ
CO CO
O Q
C JJ
3 tl
Sl
JJ Q)
*J OS
O
0) Q5
cc QJ
0)
•H
iH
0
M
a
!c
o
03
•H
1
W
(N
en
i
J?
d)
S
T
O
»-l
o
tH
rH
O
C
•H
M
(0
1
o
[Methylis
'
en
o
m
o
3
i
CO
'c
o
•H
fO '
,J-J w
'
1 JJ JJ
QJ C C
OS CJ HI
• ti-^0
c ty >i
•H JJ CO
S c -o
[H —
M tl
— T3 ^ S
JJ — "x.
Q) O Q)
CO C CO
O -H
QMS
co M Q, cy
• QJ Q) O -H
X i-f .C M CJ
CO C JJ O >i
S 3 O\ CJ
CO CJ tl
Q.JJ (0
a.
• CO O -H
x s n o
(0 O >
M • • 0)
•H X X to
O Q) CO O
CO H S Q
•H ft, CU ty
QJ •— • jJ CO
< ty c S
- ro co ty
X 05 CO .C
ro 0> jJ
2 -HO
c
3
1
c
• 3 TJ —
.H ty o
G,M JJ CO
a,< o -H
< — c s
• 0 CO Q)
C JJ CO £
-H co cy jJ
S 05 r-t 0
w"
E
tl 1
O ro — *
Cw CJ >.
iw C
<*-( O
Cd
U3 (0
•H
— ja
C I >0
O —(ti
•H CO*
JJ JJ O -H
(0 C E
CJ QJ -H -H
•H E ro JJ
•H Q.-H C
OcH £1 ff,
' CU 3 O -—
< tr w
M O H
* -HO
a> c E JJ
• a o -H o
>I-H -U ro
EH JJ C EM
CO <
C 0 — C"
O -H C
•H ^H QJ -H
jJ aa o
ro a. >* c
CJ < EH (P
•H 3
G, C? O >4-i
' Q. C CO C
rf .H y-1 M
EH
Cd -H 3 >,
S-> E-t CO CJ
IH
CO
•
z
o
M '
1
M JJ
. o
ca c
05 O
W 'O
05 • —
OS D
O CO
10 g
U 1
s §
M . Z '
C5 \
I-H O
iJ O
U g
CO 1
Ed Z
§ i
j7
c
o
u
•J
EH
CO
D
a
z
M
Q
1
Z
o
O
M
E"
<
D
Ot
a
3.
O
O
ty
w
o
*
±*
o
o
2
M
O
u
s.
CO
Q
CD
Z
RY DRILLIi
Cd
/ td
05
J •
tH
. O
CM CM CM CM CM ' CM CM
. O O CJ CJ ' CJ O • .CJ
co ro n 'to m, co co co co
iH iH CM t-l CM T-H tH ' iH «H
CJ 'CJ O,O CJCJ CJ O CJ'-
• ' • • , - " ;
CO 'CO COCO COCO CO CO CO
Z 2; ZZZZ ZZ Z.
CO ' ' . CO COCO COCO CO CO CO
Z Z ZZZZ Z Z.Z
CO i " "' CO COCO COCO CO CO CO.
Z, Z ZZ ZZ Z Cu Z Z
§
CJ
o
O ' •
CO CO COCO CO ' CO - CO O CO CO
Z .Z ZZ ZZ Z Cu Z. -Z
O _ ' • " Z '' Q
1 . -- ij ' . . 1
~ Z • (£, Z
O , Hi O-
Z -OS Z
CO iCO CO CO CO CO CO EH CO CO
Z 05 Z Z Z -Z' Z Z CO Z Z 05
O . Ed ' O
Ba: o
D5 Q
z . ' ca ' z
CO 'MCO CO CO ' CO ' CO ' tOEnCO CO HI
Z Z ZZ-ZZ Z ZZ
ex ' a, . .a.
, o* * + * i * * *o* * -o
tl tt S-4
CD • O .O
r- - o . or- r'-O ^H o r-r;
OJrHiH-' O* • \ & t~* ty
> • co >> roco - > co
D > . > - O > .O
, " in ' •
- o
tH ' ,H ,H -a- rH
• iH iH • . •' • iH
i-3 J ^4 i_q J J CO- >-H J "
'CJ CJ ' CJ O CJCJ CJ,. CJ O
CO CO COCO CO CO '' CO CO CO
JJ
O tl) -
cy ty QJ z«H .'ty QJ'
CQ W CO £1 , , CO , 10
JJO JJ - JJO r-H QJ JJ -H QJ -H
JJ^HJJ, JJZJJ JJ^HJJ .^HQ. JJZ-WJJ-HJJ
•HO) -H -H 0) fO -H ' -H (U
E.Qti 'E^ti v£J3ti C E ' *• tt E.Qti
tifOO ttiHO ticQO OJJ 'ti«HQticoO-
ty-HM-i. aJty'w tpiHi-i o •• ' ' a; a) »*-t ty^nu-i
ccty croty cccy o . cratu'cc'ti)
HlOrH HiiHrH . MO-<~H Z"* < .HiiHiH 1— i O •— i
jjocj jj"ocj jJ*oo JJ*.Q • jj'oojj'oo
C Z -H ' C -H C Z -H C CO C -H C Z -H ..
E-a eo'a • s *'a' " • E-H e'oa i **a *
jj — ^cu jjzti jj — ex jJrH , JJZQ.JJ — a.
QJ.C ty- tuc tofi ty^ QIC
tlQJjJ • tl— JJ ttQJjJ t4< tt ^, JJ , U Q) 4J —
JJ3O 'jJiHO JJ3O JJ JJrHOJJ3OZ
crz , roz crz ,JJ roz crz ' "rt;
QJQJ ty-H too)' cyoty OJ-H tytD.o
«H J3 tl) -H -H Q) -H J3 ty" -H 3 -H -H Oj" -H J3 ty Z
cOWjQ rO-Hil (0 co _Q tOiHCO fO-Hja cocoja^-*
> •— co > — rO > — CO >tp-H '>*— ro >• — • - to
H — CJ ti — CJ ti — rj .H J3 J3 ' tj — CJ tj — CJ CO
CUD^-H Q)CT»'H tyC7>-H. tyr04J OJO^-H tyt7*-HE-*
ttCOCU tiCOCL ticoa ti'CO" tiCOCXtiCOD,<
Oj ' — ' fiC, CU <, CU <, CUO*)-! ' CU •— (=C . CU fiC CU
-------
«r
r-*
f"
I
»-t
+•
*n
S
3
"
£4
g
85
<
1
i
*
to
"
01
g
•>
tn
O
f" e
jj
S
J«J
-1
0
& a.
V
3
1 ,5
.C
' §
i
1
1
i-f
1
j?
CM
»~t
^
0
g
H
1
1
g
o
N
O
|
O
[M«thyli«
S!
8
f
«
O
a
c
o
JJ
Q
JJ w
aj g TJ
n-5 5
3 JO
1
« o
C *4
O -1
~4 CO
JJ «
ra *H
u 0
Jj
u
'o
s
5 T3
o u
fl) 5
u o
f-4
ll >
0 C C
o: u w
• t. 7?
c a) >i
•H JJ Q
W U
~-TJ< 0
JJ — ^.
O O S!
w c «
O w Q, O
• O C O-l
XrH f U O
3§fte&
• n a*u
Qi AJ (3
CL ra a*
x aei
131 s
rH • . <0
-i x x n
o e> o o
CO t- S Q
-4 S o^
O.— JJ «
o. o — t
< o c s
• ana
x a: n j=
W ® AJ
c
3
t
C
•-^ 3 w "fl)
Q.M jj m
- 0 « S)
C i> « J=
sS-. o
•s
I ,
£ §>;
•4-4 l-t
u-i o
ta
< ra
o -t tt
*H CO
4-1 JJ O *«•*
s §-«5
•H e ra j->
rt^ O* M
(U* C 1 J-l
CXO-H U
•S'-SSfi
cgSo,
O -H C
•H ^ O -H
jj a. a. o
a a. >.c
O < f- 0)
~< 3
•-( » 0 — 4
Sgg'S
^-S-S"
SS3&
W
CO
§
H
M iJ
S c
, OS O
CC '—
ce: a
O td
S g
&: i
J z
CO O
M 2
o •--
H Q
>-3 O
US O
CO 1
Ed 2
CO O
D 2
•«r •T -^«
CM CVJ cvl
O O O
i-f i-H CM (H
O O O O
CO CO CO CO
2 2' 2 2
CO CO CO CO
2 222
CO CO CO CO
2 222
~
1^
c
o
O CO CO CO CO
— 2 222
Q Q
O O
S ' °
z z
o o
z z
CO CO O) CO -
a: z z z z a:
o o
§0
Q
Z Z
M CO CO CO CO H
Z Z Z Z
a a
3 * * * * 3
0 0
-a- CO CO VD
m • tn tn s w
S S S
^.
«H ...
(H i-l i-t
3 333
CO
j j .j j' i
O O O O CO
"CO CO CO CO >•«
CO
C CC.
•H Q) ££
H CO EH
Q 3
CO
jj j^ J2
C 4J W
o a {£.
—* (0 O W 02
2 i— I (-1 fl) U
^"* *H J~* ^Q 1— t
CO JJ CO O §
w •§ c^. co
Q* HH E < CU
CM
O
CO
O
CO
o
CO
2
CO
2
§ ,
CO
2
CO
2
CO
2
T-*
CO
3
CO
s
J
o
CO
4J J3 '
>i O
s"i
-H <
JJ 0)
3 2
4J C
COO)
0) -H
i-l «>-H
JJ -H JJ
3 M 2
Cv]
O
co" -^r
O O
O Cvl
n cvj
< 0
CO CO
CO CO
2 2
g £
CO CO
2 2
CO CO
2 2
CO CO
2 2
i-i in
ro
CO
3 3
CO
• n co
in o
3 3
J J
O O
CO CO
a>
jj -H
CO Q.
C 4J.
-H O
.' t-H ^3
S53
0)
— o o
JJ JJ
COO)
QJ a -H
JJ 10 d
JJ 0 4J
3 CO 2
CM
o
CO
r- t
o
CO
o
<
CO
2
CO
2
CO
2
CO
2
CO
2
§
CO
3
m
t-t
3
J
U
CO
o
-Z 01
~~ n
4J 0) W
M .Q -H
COO
3 J3
atment (rei
t/maintenai
s, Not app.
0 C .H
ull
c> W«H
S CO <
5-
CO T
r— t C4
O O
o co-
co r-i
< 0
CO CO
2 2
CO CO
CO CO
2 2
CO CO
2 2
CO CO
2 2
CO CO
2 2
CO CT>
r- •
CM
3 3
CO 'CO
r-1 in
3 3
J J
0 ,0
CO CO
o
2
(0 O
£ -H
-U Q«
3 a
^H O
•H CO
c c «
M aj *H
E a) *w
jj
0) C -H
JJ CO (0
C O
-------
E-i
I
C 4J
3 H
o: o
a*
JJ QJ
Q.Q
a) a:
Ctf Oj
CO
c
o
JJ
ro •
JJ CO
-rH (D
' CD £ "d
W -rl O
0 J CJ
' tJ
CD
3
W O
C .H1
O -H
.JJ tO
-ro -H
JJ Q
1
•H
Q
2.
D TD
O
-H jj ro
s c TJ
i— i •— ••
< — ro
— T3 < cy
— CD-v >i
cu o 1i)
w c w
O -H
Q to S
co ^ a a>
• (D Q) O rH
x rH j: M cj
ro c jj o >
S 3 0 -v.(O
CO CD JH
D-JJ ro
a to , •
x a i -
S cd^. 0
rH • • (D
i-. o cu ro o
03 CO E- S Q
•d • M "O
i-» .H <
•3 -S-2
CJ o
'o -H CO
g 4J iJ O -H
O 10 C g
C O 0) -H -H
•H -H g CO 4J
H ~H O.-H C
N Q, D O —
ffl < C1 14
•H U O H
5- -H O '
a c g w
o a o 'H o
O >-r4 4-> (0
•H E-< 4-> C Cu
H 10 rt
>1 C O — Cn
* 0-^1 C
*> -H ^H Q) -H
di 4-) a a o
S ra a >i c
— o a; E-. a)
-H D
OJ —( ^ 0) ^
en a. CP o <4-i
o ac ra-c.
o M 'H a >
TO E-« &H en O
« M
U CO
-
\ .
_
'
rH
EH
CO -*
H JJ
0 -
U C
cc o
g -H
a a
o u
Eu ' b]
Eu
• S j:
CQ O
t-t 2
0 ^
M a
»J O
w o
; CO 1
Cd 2
CO O
JJ
C
O'
0
Q
tu
^
'O
o
O
•Q
i— t
a
o
C5
CO
o
~
JJ
c
8
CO
U
CO
X
CO
a:
O
3
o
- 8
RMER'/CANNER
|
o:
to
' CJ
rH
a:
D
'CO
S..
,-J. •
. CJ "
o
CO
p
CO
z
CO
CO
, z
CO
z
CO
CO
•z.
,
r~ •
en
3
eft
iH
S .
J
o
CO
0) Q)
U W
C - D
4-> W
0) O -H
4J z x:
C ' 4-1
^H -.
g c o
^ (U (w
C Q. Q)
t, Subseque
ensing equi
t applicabl
c a. o
0) W Z
6-rt
4J T3 -
<0 0)
0) O ~H
W -H J3
4J 4J CO
CO O
CD O -H
sag
OJ _ • CM ' ' / ' -
CJ . , CJ , -
02 "c* ' CD nron n n "co^r
r-H OJ - rH CM CM CM "CM CM CM CM
0 cj -.u :• cj cj cj ' cj cj u o
CD. CO, CO 'COOOOO OCO'
o rH o onn foc'O.n'rH
< 'cj fC rtj ri; ri; • - rtj <• ri|o
1
S
r . " ' • "
CO CO CO, COCOCOCOCO COCO
2 2 2 22222 22
CO CO CO COCOCO COCO COCO
2 2 2'222- 22 -22
CO .CO E ro 'xi 3 3
ro c -H , a> cj re *.
C OXl JJ^ CJ CO CDJJCO
CD (0' COrH' ' -H' -r) iHO-r{
jJ jj jj 'U >iQ, . iH £ 32JS
CO O-H 'CO.O- TJO. "D4J JJJJ
-H2 2-H < (DO. CDJJ .CJ-
fa . Q. . o> GJ rtj CDOIH rejJti
E*-O* COC-U «w ,'.3rH -3- 3 Xl"X» , 3 Xl
CT-HCD c CO-OCDCO :CrHW 'Ccoro c^crro
CDHtO -^ i-iXl-H -H(D-rl .H^HO CCDO
COCX3 CCU C^-rirejin *-) £} JZ ' 4J -H -H -H
•X1D, '0)rH Ci CJrH-U - CraJJ , CCrH JHD>rH
3o 'roo
(D rH CDCDCO &J
-------
t"
1
,
U1
(O
M
3
g
i
"
<
i
SJ
CO
o
#•4
|
I
S
o
o
I"
aa
|fj
r^
9
C
•H
"o
' a
2
2
I
ro
HI
5
1£
T
•«»
o
o
i-t
g
~
c
2
o>
g
•rl
I
.1
N
1
S
0)
C
O
JJ
R)
u «
•H 0
sj s "O
=§3u
•o
0}
c 5
o -4
u «
13 —4
u a
j
c
£
G
ra
u
0 T3
1 AJ 1J
9) e c
ffiU M
• u to
—4 JJ CO
E 5 H
M &4
•31 <—• (3
— US! >,
0 O ffl
n c w
(fl lJ O. CO
« CO ffl O -4
X-4.C U 0
O C 4J O >t
S 3 O|^ O
" SI u
Q* (0 S)
x a a)
• «S O *-4
gsbR
w4 X X CD
- M T3 — .
t—OJ M
O — t
0) C 2
• ra to <% O -H
<-c g
C JJ « £
^ (0 O -U
to
1
£ §>
4U O
to CO
•H
e I ^o
O 1-4 14
-4 C U
JJ JJ O «H
8S-5
•HI g « JJ
—* Q.-H C
a-H j3 ^
as o —
r«r M o
. ^40
n c e jj
ao-4 o
>4-4 U (0
E- jj c 1*4
•23 ni5
•u Q. a o
SD. >i C
«C E- CO
M a
a. c TO c
S ^t
U-H a >
H H CO O
M
CO
t
z
o
f
s
H
CO —
M JJ
Ci] C
Ld O
§ g
^ g
J Z
§ 1
M a
b] O
CO t
ti3 2
CO O
0 2
JJ
C
8
*"^
M
D:
CO
Q
M
a
i
Q
w
•a;
1
a
o
L4
e>
n
I
CO
Cd
«
o; -
CO
s
1-4
S
ttf
u
PULP/ PAP
ro
w
0
o
a
CO
2
2
CO
2
CO
2
CO
CO
2
VD
CM
r-
.
S
O
CO
CO
3
CO
- S-t
4J >-l O
G 0) 1-t
0) J2
JJ (0 CD
WOO
0) *H
JJ JJ iH
c o a
w 2 a
jj"« jj
C -H O
Q) (0 2
e-*
jj jj ^
tO -H 0)
JJ — (0
— O
W CT-H
a? 3 —i
JJ.-H a
ta w O.
s — <
ro ro
CJ O
o o
CO CO
2 2
CO CO
2 2
CO CO
2 2
CO CO
2 2
CO CO
2 2
CO CO
2 2
cn VD
m CM
3 3
if) r-
rH
3 3
•--, -^
CJ CJ
CO CO
a>
CO
JJ 3
o
2 «
•H JJ
0)
.a w
JJ ffl O
cu
JJ C 0)
JJ O --*
-H .Q
e j-> fo
U O O
QJ S -H
JJ -H
c^-a
* c
JJ 0) JJ
C 3 O
CU CT2
£ a>
JJ CO *
a X) a)
(1) 3 •-!
M CO J3
M 9»-^
• a) 3 •-*
JJ -H Q.
(0 W O.
ro
CM
CJ
o
CO
2
CO
2
g
CO
2
CO
2
CO
cn
OJ
3:
to
,_^
S
U
CO
tu co
JJ .Q -H
(0 (0 .C
3 ^ JJ
CM
O
CO
u
o"
a
CO
2
CO
2
CO
2
CO
2
CO
2
CO
2
*
VD
CM
t-
.
S
CJ
CO
J-l
o
•H
(0 0)
tt) O
£2 -H
"•a.
- a
O* RJ
3
4-1 JJ
W O
•*-* 2
O •.
O 03
CO J3
(0
- t>
JJ -H
C H
QJ a,
E S
4J <
(0
tt) aJ
WOO)
jJ 2 (0
3
a a «
CM
CO
o
CO
§
§
CO
2
CO
2
CO
2
CO
2
CO
2
,
VD
CM
t^
.
3
U
CO
o
0)
I—)
c ja
0 (C
o
JJ -H •
O i-t
•* (0
3 JJ
r-H O
CO 2
co m
o
-•H
4J *— 1
c a
1£
4J
(tJ JJ
(U O
W 2 0)
JJ CO
•* 3
Q) G) CO
3 •— 1 JJ
CM '
O
ro co -a* -T " ro -^
CN tH CM CM CM CM
CJ CJ O CJ CJ t_>
• CO O O CO CO O
o ro ro t-* o fi
*s; rtl' *C cj ri, rtj
CO CO CO CO CO CO
222222
CO CO CO CO CO CO
2 2 2 2 2,2
CO CO CO CO CO . CO
222222
CO CO CO CO CO CO
222222
CO CO CO CO CO CO
Z S 2 2 2 2
CO CO CO CO CO CO
222222
\D VD VD VD p- •£•
CM CM CN CM CM CM
p- r- r- r- co
3 3 3 3 S S
CJ CJ CJ O O O
CO CO CO CO CO CO
-------
r- •
„
0
to
Oi
I
•
.
CO
o
9
K
rtj
: X
tH
1
P*
CO
•"3*
O
tH
£
E-
Report Run Date: 09/03/98 -
PRD Report Date:
r— >
s
•H
O
. N
«J
•P
o
CO
•H
1
tc
co'
1
1-1
1
'•'S
,1
CM
t_-
O
r-t
t-
O
rH
3
Q>
O
"o
B
O
Case 3092 [Mathylisothiazolin
.
to
1
OJ
m
4J to
•H 0
0 £ "O
(0 -H O •
ID J CJ
•a
Q)
CO 'O
C -H
O rH
•H (0
4-1 M
4-> Q
1
CJ
C
ST3
0
0 3
C3 O
i- 1
l-t
&>•
1 4J 4->
0) C C
a; Ct] w
• t-t CO
C .0 >i
•H j_) fO
M i^
•3^ < — fO
•— • *O (^ Q)
•— ' 0 --v >1
4J — -s.
0 O OJ
W C CO
O -H
Q CO 3
co s-< a 0
• Q) 0 O -H
fO C 4J O >.
S 3 O --. O
to 0 L4
O* XJ (0
Q, (0 0
< a: >
•^.
x a 0
• ro O rH
X 2 M O
ro o >,
S <2^ O
-H X X M
O 0 CO O
CO E-* 2 Q
• rH "O .
Q/ — JJ (0
a o -H
< 0) C 3
4-> t-l
• ro w
a
i
c
• D -O —
r-t .00
ti M 4J CO
CLrtJ O *H
(=C — C 3
* 0 W CD
C 4-> CO ,C
•H (0 0 4J
S OS ^-f*O
W
1 - ,
W 1
O (d — -
Cn 0 >,
iw o
C£I
"-3 (0
-H
• — • J3
C I >t O
O rH tj
•H CO
4-> 4J O -H
ro c s
SITE Application Type, Applic
Timing, Application Equipme
Surface Type (Antimicrobial
cy Influencing Factor (Anti:
. §
H
USES ELIGIBLE FOR REREGISTRAT
J
M
02
£1
a
M
a
o
S
r
z
o
o,
-g
3
o
••
a
0
,
o
CO
D
CJ
<
S
§
M '
NON-FOOD/NON-FEED (con't)
SECONDARY OIL" RECOVERY INJECT
' rr
CM
U
CO
iH
CJ
CO
CO ,
2
CO
2
CO
2
CO
2
CO
2
.
n
S
-=r
t*J
S
^
i
cy
rH
O
•o'a
0 PI
Q) eC
Water treatment, Continuous -fi
(initial), Not on label, Not ,
Not applicable for this use
en
CM
• U
CO
2
CO
CO
§
03
z
CO
2
^3.
s
•^
ro
S
^
U
03
^,
-------
e>
3>
q*
a
u.
1
rl
«A
W
»»«
3
I
o
i
i
N
M
ffi **5
» « si .&1
y 9
< 1
£ "
6 S
£ r-
S S
to o
«ar -rl
o i
•H ,£
|
P e
g
I "H
§ 1
8 1
5t o
§B
•H
•H
SS 1
SB i
JU
t* o*
to
8.0 2
i£ S
0
JJ
JJ W
a* S "O
•o
K O »
jj w
Q -H
JJ 0
O
1
a
gj 5
(2 O
^ >
I U i->
& C C
s: td M
.£»
C Q} >»
•Hi iJ ft)
M •*-»
H» U
< — (0
— T3< 4»
— a-*. >*
O O 09
n c n
S»|
W £ Q. S»
• O QJ O ^
X-H£ U O
<0 C u O >i
Z 3 CH-« O
W Sfj In
D. ffi €U
< S >.
x a. »
• *g o -<
xs u o
S
-1 • • 41
-i x x ra
SO fil O
H £ a
• M TJ ~
-4 < ej at
a~jj ra
O. O -H
< JJ C 3:
• ra n si
XOS M XT
19 tt» JJ
I -10
3
1
C
• 3 T3 -^
-t 41 ai
aS o -H
• a> n a)
c jJ to jr
Sts * o
n
I i
O ro —
!«. 0 >,
IM O
— i
*a ra
e t >>o
o — * »-i
-) CO
AJ JJ O -H
8c E
01 *-i —I
-< e n t>
-t CL—l C
e. -«a>-H JJ ra
t- jj c £
a <
c o — w
O -H C
-4rH O-4
jj a ao
•H 3
tc? O *w
c a c
-«M H
U53>,
f-if- W O
M
W
§
M
1
S »
u c
Oi O
So
—
B: a
SCd
ta
Cii
£t3 1
J 2
M 2
i-t O
CO O
3 2
n
CM
o
CO
— 2
c
O CO
O 2
,J
< CO
n 2
Q£
E-
O
1-1 CO
2
Q
Q
1
0
O CO
M 2
H
O
< CO
2
a
3 *
8
o
a> VD
CO
tH
^
— »J
O
C CO
0
o
s
I
o
td
t-t
a:
cc
M
O
f£
1
CM
O
CM
CM
CJ
^
co m
i-l CM
0 0
CO CO
2 2
CO CO
CO CO
2 2
CO CO
2 2
CO CO
2 2
CO CO
2 2
* *
CO CO
s s
n co
CM CM
S S
J J
o u
CO CO
-a-
CM
O
^
CO
t-l
CJ
CO
2
CO
CO
2
CO
2
CO
2
CO
2
*
*
in
CM
ro
•^ "
CM
^
CO
o
CO
0
4-1
.-I
O ffl
O
O H
2 a
- H
s <
(0 -P
0 O
AJ (0
01 0) CO
T
CM
o
fc
CM
CM
CJ
CO
CO
•2
CO
2
CO
2
CO
2
CO
2
CO
CM
s
CO
o
^
,J1
' CJ
w
a>
o
c
(13
a)
jj 4J
-H 2
laT
GO (0
3 O
CT-H a)
•§ s- n
CO -H
c x M
JJ (JJ
(0 J2 CD
4J ro
c o
M O -H
0) .-H
CM
CJ
co" -a-
rH CM
O O
^ ^
CO CO
O «-4
< u
to w
CO CO
2 Z
% %
CO CO
2 2
CO CO
2 2
S §
* *
CO' CO
m in
S S
CO CO
CM CM
S S
rJ J
CJ O
CO CO
m
CM
u
„
CM CO
CM CM
O CJ
CO CO
CO CO
2 2
CO CO
2 -2
CO CO
2 2
CO CO
2 2
S i
* *
co en
S S
•
<"•> CO
oa CNJ
S 3
J J
O
t4 W
O
n
«. -H
JJ ,C
C JJ
CU 4J
4J 2 O
(0 4-1
*->£•-),
> O
•H D*-H
"S -5 "a
0) JJ
S s o
a ^
0 -
J-i O <0
JJ (D O
CO 4-1 -H
C RJ Q.
H-g <
-cr "• -O1 •«3I
CM CM CM
CJ O U
» ^ .• ' ».
co co ro co
i-l rH CM1 rH
CJ CJ CJ O
V
CO CO CO CO
2 222
CO CO CO CO
2 222
CO CO CO CO
2 222
CO CO CO CO
2 222
CO CO CO CO
2 222
CO CO CO CO
2 222
CM CO CM LO
t— • CO
in to
3 s s
0,
o ...
rH i-l CO
S S & S
J fj »J _^
CJ 'O CJ CJ
CO CO CO CO
c
-H (D
(-1 CO
D 3
01
* -H
JJ .C
C JJ
0
J-> O O
(024-1
JJ <— ) i-l
> nj O
-H -H -H
1o c*a
0 4J
020
a - "^
Q> •*
M cj ro
JJ to O
CO 4-1 -rH
-------
f
a\
rH
(1)
cn
ro
cu
1
iH
in
co /
i— i
»
rH"
Pi
9
2
X
H
g
di
<
CO
•V
o
1-i
cy
£
•H
/03/98 -
a\
o
cy J
jj jj
ra ra
a Q
C JJ
a
jj 3
00 •-'
3
& >
1, JJ JJ
cy c c
a: cd w
• J-l CO
c cy >
SS-8
W —
< •— ra
•— • cy *^ >, L
cy o a)
to c «
O -H
QMS
co j*j a (y
• Q) CD O -H
XM jC M O
ra c jj o >
S a o -N. o
« tD H
Qtjj ra
a ro a>
^ """»
x a ty
• (D O -H
X 2 M U
cd o >i
S i
•H i— )
y-i o
Cc] .
rH
L» ra
*H
c >3
O ^H S-l
H CO
JJ JJ O -H
0 C g
O (U ~H .H
H g ra jj
•H a-H c
a-H ja a:
2. 3 O —
eC D- u
u o n
•H O -
a> c g jj
3» O -H O
>t-H jj ra
E-* JJ C En
ro <
c o --1 DI
O-l C
H ^H 0) -H
jj a a o
a a > c
SITE Applic
Timing, A
Surface T
cy Influe
• §
M
i
E->
W —
M JJ
. O
Cd C
o: o
f.l M
S ~
o: Q.
O Cd
^ g
3 i
USES ELIGIB:
NON-FOOD/NOl
CM C\]
u o
CO ^T 03 ^
«H C-J t-H 6j
O O O : u
03 CO • CO Co"
O f-t O ^)
< u a; . cj
z z z -z •
CO W CO CO
z z z z '
co en ci w
3 . Z Z Z
J7 '
c
— z z z z
o
1
O L
CO CO 'CO CO
g 3 3 .2 z .
0
z
tH CO C/3 CO CO
>g 2= ' " 53 S 35-
D * * ' * «
o •
S-l -
O '
0) "^ ' o ^ ^
co n n m
> > 3 -
r- •
i— 1 • rH
"**«• *>- "**. "*•*.
CO CO CO ' CO
C , JJ
O 4J O
o so cy
— •* JJ 2 co w
JJ 0 3 JJ JJ Si rH Qr-I^
C£ Z JJ J3 Q) J3
Cb-cy OT cyocy 0*ra *jara
. J -H ^H J2 -H 3 -H O -H C -H -rt
5 " > « U >fflH >Ca ^Cfll
EH i-t^HO s-i ^2 x j^ 0 ra nj ra
co cy,1*-* cyrajj 0jj 0jj
D W'C COr-H COCJJ. MOJJ
M cl 2> Q. C ° M ro ^ s
J ' ii «— i o* • M ffl i-i3ra ^Ora
<; ajracu jj«*o jJCTtj i-irao
J-H w .H ro w r-t ^H cocy-H cyiM-H
O 3JJ 30«-l 3WrH CO 3 •— 1
CJ "O-HjJ "OJSCL "O .Q Oj fli p p,
CO MI— i 2 M •— i nj M CO' rtj Cu £ ^
cb
i-H
O
oo
J
^
U
H 4J
O
-3
raoa)
>2to
S s
Q)^
81-5
5 a
"
CO
Q)^J
.13
5m
too
M- * a
S^-J
-------
N
1
B
£
r
1
H
3
in
*
Q
(
g
0
r
{
n
ev
o
i
te-. 09/03/98
tc:
gg
!!
bo:
.,
V
a
1
!c
S
•H
I
j i
i 5
! i
i i
t r-
4 O
: H
1
a
i
S
•3
g
1
Q
•H
1
1
1
j
c
o
JJ
xj n
n^ls
n o
C ~4
O -1
-1 0
Q -H
JJ 0
"t
_0
x:
0
R
8?
© 2
U >
1 JJ XJ
C CJ X
«4 J_f tg
WH"\
< — ro
— •a < at
O O 6J
n c n
Q »"i
n ^ a Q)
• Q) fl) O •-*
X-H .C U O
3§fk&
CO 3d i4
til
x a. ai
• (q O ^
ifks
-1 • • 0) *
-H X X W
o e a o
(0 t- S £5
.4ss.
8TS.3
< 0 C S
• (0 w a)
X OS « JS
i .33
C
t
C
r-4 # "a7
tM u ta
< 0-4
5
• si n d)
C JJ M JS
xS-*o
¥ .
^ i
£ |5
•u c
tu o
CO
u> 0)
c i >;•§
5 28
3 1*5
•*H ^ ra *J
0.^4 ^ KC
ion Type, API
lication Equ
e (Antimicro
ing Factor (;
4J ao. o
o a > c
0 < E- 01
Q.C ra c
U -H 3 >.
t> E-< CO U
>H
CO
1
H
CO —
O
Cd C
K O
Ci3 O
K a
O f*t
£ u
cu i
m o
1-1 a
J O
Ci3 O
lu
CO 1
U Z
CO O
s z
^J
"c
8
o
£
o
a.
8
z
a
3
O
CO
JJ
1
CO
B
DUSTRIAL PRO
2
M
SPECIALIT
T
CM
CJ
CO
,— 1
tj
CO
2
CO
2
CO
2
i
CO
2
CO
2
•f
CO
vo
CM
>
»J
8
^,
CM
CO
!— (
S
CO
Z
CO
z
CO
z
i
CO
2
*
rH
CO
CO
CM
>
J
CJ
CO
^1 ^«
CM eg
O O
•H CM ' CM CM CM
CJ CJCJ CJ'U ' U CJ" CJ O
CO COCO COCO COCOCO CO CO
r-t ^HO t-HO tHiHt-H r-*,CM
O CJ< CJ< CJ CJ CJ ' CJ CJ
CO tOCO CO CO COCOCO CO CO
2.22 22 222 2 2
CO COCO COCO COCOCO CO CO
2 22 22 222 2 2
CO COCO COCO COCOCO CO CO
2 22 22222 2 2
CO COCO COCO COCOCO CO CO
2 22 22 222 2 2
Q
O
&
z
2 , . .
CO COCO COCO COCOCO CO CO
z zz zz zzzccz z
8
Q
• - 2
CO COCO COCO CO CO CO . M CO CO
2 22 22 222^2 2
a
* *•* ** -jt^ + a* •*
o
S-l
CD
fo- r-r^ r^T cncrimcM CM
<0 •
> CO^T COCO CMCMfOMtO IT)
>> >> >>>°-S S
TT T-) r-H CO CM -W ^T
r- en
CM COr-< CO- -cHr-) c-l i-H
> >> >>>>> S S
J JJ JJ JJJ J J
O UCJ OCJ OOCJ O CJ
CO COCO COCO COCOCO CO CO
•U O» • .
o c
CO 20) -HO)
.. , ^^H CO ^ CO
t i-5 4D S D
D 3 CO CO W
a an ^ -H r 'd
o ro jc jj - j^
C3> ty'W «-f JJ C JJ
C C Ed 0)
-H-O .HCU CtJ C3EJJM
tJOJ ^.H OO <4JOO
'QJCO fl)XJ 'w Qro21*-*
jj 3 jj (o JJ a: CD
.-e ja --s. a ja
^^cn -^a. •.<*(& cooj^aro
jjc jjcuci JJQJO os>roo
COO CUro CO-H .td-H'H-H
Q>C--) 0C OC«H CQ4J«-I
E nj £ ro -t-> sroQt Mroccu
JJCQ jjco jjca tu>oa
foc>2 roa>2 ajcuro nto
CU4J CDJJ jQ CO-H>JJ.Q
>3Oj' >3Q. >3.(D CuJ-tOnJ
ncra ntra ncro JJJITJO
a)rt; d)d)-H M to
-------
1
tH
CM
CO*
(0
cu
1
.
m
CO
3 '
^
?
•H
•H
O
*
1
O
tn
•H
» 1
SB
w
*** *i
§ , 1
d» i
s -
§ S
1 S
•3
01 O
Report Run Date: 09/03/98 - Time 10:
PRO Report Date:
Case 3092 [Methylisothiazolinorie] Chen
«
c
o
•H
fO
J-t CO
•rH 0)
o> e TJ
W -H O
ED i-3 CJ
•o
0)
tog
C M
O -H
•H (0
JJ CO
ro -H
JJ Q
E
U
.C
Q
fO
o -o
O Q)
So
i-H
rH
> .
1 JJ JJ
a> c c '
c: a M
• H co
C 0> >i
"sen
HH "—
M M
rtj • — ro
— TJ < <1>
*— T
Q) o CD
to e w
0. -H
w n a, O
to C JJ O >i
(0 0) ^
Q,JJ ro
a. ro a)
*C CC >t
>,
x a. 0
• 03 O -H
ro o >i
S o|--«. O
.-H . - 0)
•H X X W
o a) ro o
co E-- s a
• WTJ— .
•H fli o> Q)
a— *J co
a o -H
< CD C S
» ro ca cu
X EC CO J^ ,
ro a) jJ
E f-i O
c
i
c
• 3 TJ —
•H "
•rH ^H
4H O
t£J
SITE Application Type, Application
. Timing, Application Equipment -
Surface Type (Antimicrobial only) &
cy Influencing Factor (Antimicrobial
, _ [•
USES ELIGIBLE FOR REREGIST.RATION
NON-FOOD/NON-FEED- (con1 tj
£
c
o
Q
O
g
"Z.
a
'8
Q •
M
a
o
0)
j
TEXTILES/TEXTILE FIBERS/CORDAGE (con1 t
CM
o ;
CO
CJ
§:
CO
2;
CO
z
S
CO
2;
CO
2
CM
in
S
^
i— i
3
j
O
CO
CO
Preservative treatment, During
manufacture, Not on label, Not
Applicable, -Not applicable for this us
ro
CM
U
CO
2
CO
z
CO
v
CO
Q
,o
g
1
CO
2; o;
j O
o
a
2;
CO M
•S t^
a
1 o
CM
0)
m co
S
". •
i-H
S"'
CO
* S
*v. M
.CO Cd
CJ
WET-END ADDITIVES/INDUSTRIAL PROCESSIN
OJ
U
CO
t-H
CJ
v (
i-
CO
CO
2:
• CO
2;
CO
2:
CO
z
eg
t-H
S
CM
r-
o
•
S
J
CJ'
CO
C'
•H
CM
, •
>
. ^
u
CO
.CO
E-< 1^
CJ O
•-1 LJ
WOOD PRESSURE TREATMENT TO FOREST PRODI
Dip treatment, Not on label, Not on
label, Not Applicable, Not applicable i
this use • . . '
z
CO
oo
J
—
o
-------
1
1
8
f"
1
.
S
.• §
«— •
d
rl
8
g
•H
1
n
- 5
< T
i s
M «-•
P* f*
HI
§
O i
8 !
' 1
Run Dace: 09/03/98
poet Da to:
092 CMothyliiothiaz
a & m
if i
83
C
0
~*
t> el
w3l3
•o
§
« o
C ft
O ft
~4 (3
u n
22
"e
o
1
R
8?
38
&>'
i u ij
eCC
c: u M
• *4 n
e ai >i
— t AJ (0
X CTJ
ft ^^
l-i 14
< f RJ
•— "O •< fl)
— «-• :*
01 O ffi
to C «
S«-3
n w CL, Q)
. ^ 0) o-i
X *-* £ U O
s§lii&
M ,
x ao
• (C O ft
!«£&
ft • • 0)
*H X X 03
W H E D
• 1— 1 ^ f^
ft < « a)
Q.'^ 4J W
a o-t
"* 5 c 2
• ra w 2)
X EC 83 f:
m e> AJ
c
i
c
. p-a —
§Sg|
* G) 8) 8)
5 a S5
Scfi-l 0
9
fi ,
£ SJ
u 0
Ml (0
H^
•^ JH
C 1 >,0
O ft U
-5 c u
iJ JJ O -^
ra c e
o a> ft -f
-t S « u
ft Q.-H C
a-t n S.
pplication Type, Ap
ng, Application Equ
ace Type (Antlmlcro
nfluencing Factor (
<_,««
SS3&
M
V)
M
1
LlGIBLE FOR REREGIS
OD/NON-FEED (conft)
w o
tu
CO 1
Cxi Z
to o
3 5£
^ Cx] ' '
CJ U
co- cn co en
t-i , CM ^ * ri
O O u o
"
i
z z z z z
1 g 'S § S S
CO CO CO W CO CO
S S Cu 3 52 5S S
g g
go.
Q I . .
Z J
0 <
Z l-»
o:
MZ zcnzzz z
E-. U '
e£ CC
O Ci3
^CO COHCOCOCO CO
&* *§•+** * .
O O , :
C5 O
d)1^ ^(ytnnjinrd- 1-1 ,
ID > o iH t— i ^
> 0 0 0 0 >
o o o o
— i — i - , -
'_.•''
eg rf CM ft
in r- — • ir) t^
Q
co ta < <
1 > 1 •
S , S
Sfj j — jh-i^ j
§OUCOUCJCJO
o m w u m
Ctf O O
t-3 (£4 o • • "w
^ *OJ U *"* W "-P H D^ C XI JQ
£J O o • O -H
Q (DM Q(OT3«T3'CJM
8O.JQ -H oca>ca>O4JQ«
n-H(QJ^ OOOOQJOOD*
. ,' • ;;. ' - . • .. • / ••' , . -; f '. >: , "'•';<; | J • '
-------
JJ
0
•r-t
3
CT
Ed
>.
•H
E -
0
a
£-•
§ .
•r-t
JJ
<0
P .
•H
'a
Q.
(0
•g.
0
E
ro
•Z.
a
3
O
J-i
CJ
CD
CO
3
„
0
E
ra
0)
jj a)
•r-l JJ
CO (0
cc
CO
.c c
a o
—1 «H
Is
W -H
CO ,-(
00.
•a
a) E
1 -H
C C
O.-H
2: 2
T3 -
O >
b* -H
1 -VJ
C C
o ro
' o
O (D
Q.
H Q.
i <
c
•H
CO
CO
M
o
4-1
0
CO
i
•H
c
-H
S
Appl. Rate {AI unless :
d otherwise)
. CD
C JJ
UJ
PO ' JJ 0
CJ JJ ,
rJ , '3 (0
0 73 *O •
D- O i
' J-l tO
CO Q..H
C J3 ;
O 0 JJ
•r4 • £
JJ O J-t
(0 : CO CD
O jj, •
•H iw
-i • ro '
a CD • '
CL . JJ 73
co ra 0
"O r-t
"3- CD
1 - CO JJ
•H CO
JZ-H
- JJ O>
>• * ' •.
o
rH CO -
•*-. w jj
•W 03 .CJ
= 3
— 73
* CO S-i O .
— (0 0 J-i
>, jj a
M 73 c •
C 0 0 .-H
0 to l u rH
CO - (0
CO 0 JJ
E J-i C JJ
-H a 0 (o
rO X E .C
rH 0 3 JJ
CJ 0 .
CO O 0
0 -H Q OJ
"O- JJ
-H = CU C
O J^ CU fO ' '
•H 03. O U
XI 0 (0
0 ^ 0 SJ " •
*— 0 73 M-i jj
O- CD , O
CD JJ . 0 C
' ' » C -H XJ CO .
4J O 3 (00 '
' X -H O rH O . •
jj to ro ro
t3 O- O ~ > CO
0 —1 -H (0 M
JJ -H-.H E O ' •
fO O Q. CD 0 V3
,M W Q. JJ i4
3 (0 CO 0 JJ •
CJ O • >i S3 ,
•-i JJ T CO XJ '
(OS jj
CJ TJ , (0 *
CD T' • .C JJ
E JJ 0 S-l JJ S-i
O ra >H to o
jj ^H Q. • CD TJ Q.
W 0 E >1 C 0 ;
CO X tr — '
CO &3 . O CO
CO 13 -H
0 0 JS
0) (D . ,~t *O JJ
JJ JJ 0 CJ , C
-H -H JJ >i 0 C
to co ro O Q.-H
OS CO
0 0 dt 3 "O
H •— I CD O CO CD
c c; ro cj ' JH 3
-H "H tO 'O --H
CO tO O 0 — O
Q M CO CD C
(0 ro * t?* > >i > -H
E C (0 -H
O O 3 -H "D JJ (0 '
jj , jj E • co 1— O JJ ' ,'
•H ro ro
C C X tO co T3 *
O ' O ro C 0
-H -H S s-i O J-t 0 •
JJ JJ 0 -H CD >
to ro jj > jj s ro
,o o to o ro jz:
-H -H = 0 JJ
-HfHtOJ-l0-Hffi>,
a a c >TJJ *H x ro
D* Q, O -H O. JJ E •
ro ro -H n co PI • *o
JJ **•* rij CO 0 0
cu cu to -^r ro jj jj ^
^,^-itj= c oros,
D* • D»-H O-0 3T3JJ
.CC«-ftOJJ0'tJOJ '
•H -H d, ra S o co ro
CO CO Q, 73 JJ "(^ -H U
< T3 0 0 aj=
ro to 0 -H xi jj c
> jj
CD Ch i-l ^ CO
O r-t to
3 >i
- co * " , XI
. — . o. co
P_( (Q p,' J^
0 CJ E O
ro •. a. jj
CD «. D*
C JJ •— ) -iH
O W r-c a)
. ~ca,. 's
JJ S' * , : JQ
ro co
•O-OCOTJMW^.gu . °cS ? §
I ||= | |&8Sf SQ 'SS-S. S-S 5
EEEcoEE-uco on « r>. —JmuniT^
-H -H .H SJ -H -H C CO -H fO C
X XXroXC0i-iDi-u F
rororo0ro-H0o0ta • i-
S SS>S-S.CiS^ij73 Ed x
E- Ei
2 a
CO Q
to . E-
0 CU 2
i-H • 0 ' CU - £1
C JJ , < U t_
3 ro w -H 2
PS CO X i CSQ.0E W Edi-
0CDS 0CO 0 QCOt03 J-lQCC
JJCO- WtOT3-JJ Eu I S^ -H 0) CD O^l
ro-^xs; <| -H -— > ro cro*DCj2 u>-
OSStO — S JJQ WOOCD-HJJ C
M S (0 • — 'J-4>C DiSOS^O EIC/
•0.(i 0tlMJJ ^3 O
€L.JJX*£ tojjjj>i'o, x &-«
a00 OOCH.Q, Ed rS
<&H=B=oi-ijj0 f 3
T3 73 CDS 0
• 0*-(. -0-Ed J Sr-
XJJ-HX XJJCIQ M ' S-^
(OOOro roo*H0oS o oc^
SCC02 S- C S OS cu . co*CJEtuO tier
lO 000"- 0*§>3Ca
4CO Xiro^CD •— iCD-Hf-l-H
--^ to--iroo . roxi0o
3Ed rH CJ0 • U'S>S
* E-" O -H ' C CU
,<• CJJ-.O, 0ro>i >cu
- K . O to , X3 O X! .XI
* EH , 0 JJ i. H
.S CD 3MCO JJC73730
Id »-H73*OiJ'-iJ O O Q) Q> £
>O X10 3CD S-HJJJJJJ
z ro-H,*ax]rH jjroro0
o o<*-ia) ^j cro^HrHx:
O 73-H-HjJ^0, ro«-l333:
CDrHOJ-ltOO. CJ3OO
Cd 73 a 0 CD JJ O-H -H C
rH 0Q*Q<>0- Ed0rHrO(O3:
CQ 0(OCJOO
s 2: ' o cr jj ff ro o c
rJ .CO JJJJO-HJ^ t2CQ SS^
O ScaooCJ-iro OOCucuc
CO O <-2 ZDXICL 2 Q Z CU CU D
^ .. . -O
< E-< '
H < CJ
> CJ rH
td M fO
CO S • , 3 U CJ
"^s CQ Cu 2
co <§E:SED D
oo
-------
CM
fil
a>
£
1
r-4
to
a
c
•H
H
0
«
0
O
a
V
s
F>
E4 *>
2 a
<< i
N
O ^
s s
O) O
o 3
« 6
ft 0
£-• e
0
C
1 -H
o
CO M
er» A
*•». -H
? 0
O% H
0 a
.... ^
00) S
u u »
§u
U CNl
"8 S
CL O
Ka» m
0°= 0
ao a
££ S
o
JJ
O • '
•H
M
S 0)
CU 0)
— £0
C
>i 0)
oj o ,
H r-H ' -
O '
X CO
3 Q,
(0 CLi
s
JJ —
C-
(0
•H *
CU
JJ JJ
c to
1
** ° '
0) ^1
u ^a
^ S, -
a) 2: . -
w O?EH
C tH
QJ . to s
J3 Q) M
4J U t-^
o
C -ae
•H W £H
M
O J3 Di
O O -O
O JC W CO
JJ TJ M
S -H C Q . , .
3: 0
o 0.--
jj m t
JJ fl) W EH
c -u E ca ,
Ol CO (0
^-t >i Q) -
(0 OT VI CO
> JJ X
•HI W O H
i-i D> s
C C (0 C =»
^) • "H P -H Z
« C JJ C .
M ra ^4 on -H Q3
O Q) (0 CU R3 33 : - „.-,
*M iJ JJ JJ EH
(0 C H C
•~ O O Q U) - - •
~ -00^. O EH
X 0> T3 • 2
X -H JJ C C JJ CO
I -H C (0 O C CO
O CU- *H CO CO
M « 3 Q) JJ 3 OS
as -H c o —t QJ
E>,tu — ( ^H <*-» Cd
-H Q) (TJ JJ Q) O "D
».C >£s«CO ^HC
e- 0*0 ra cu CD cucr'CO too
Sty— WE.CH-H tjco era
|£ O -H (0 QJ flJ EC
u«S "Tj-S^ aS w u 2 .
rf-aIi2cc-O(o-H:o
-------
GUIDE TO APPENDIX B ,
Appendix B contains listings of data requirements which support the reregistration for active
ingredients within the case methylisothiazolinone covered by this Reregistration Eligibility Decision
Document. It contains, generic data requirements that apply to methylisothiazolinone in all products,
including data requirements for which a "typical formulation" is the test substance.
The data table is organized in the following format:
1. Data Requirement (Column 1). The data requirements are listed in the order in which they
appear in 40 CFR Part 158. the reference numbers accompanying each test refer to the test protocols
set in the Pesticide Assessment Guidelines, which are available from the .National Technical
Information Service, 5285 Port Royal Road, Springfield, VA 22161 (703) 487-4650.
2. Use Pattern (Column 2). This column indicates the use patterns for which the data
requirements apply. The following letter designations are used for the given use patterns:
A Terrestrial food
B Terrestrial feed
C Terrestrial non-food
, D Aquatic food
' E Aquatic non-food outdoor
F Aquatic non-food industrial
G Aquatic non-food residential
H Greenhouse food
I Greenhouse non-food
'.•-.. J Forestry
K Residential
L Indoor food
M Indoor non-food
N Indoor medical
O Indoor residential,
3. Bibliographic citation (Column 3). If the Agency has acceptable data in its files, this
column lists the identifying number of each study. This normally is the Master Record Identification
(MRID) number, but may be a "GS" number if no MRID number has been assigned. Refer to the
Bibliography appendix for a complete citation of the study.
87
-------
APPENDIXB
Data Supporting Guideline Requirements for the Reregistration of
Methylisothiazolinone
REQUIREMENT USE PATTERN CITATION(S)
PRODUCT CHEMISTRY
61-1
6 1-2 A
61-2B
62-1
62-3
63-2
63-3
63-4
63-6
63-7
63-8
63-9
63-11
63-12
63-13
Chemical Identity
Start. Mat. & Mnfg. Process
Formation of Impurities
Preliminary Analysis
Analytical Method
Color
Physical State
Odor
Boiling Point
Density
Solubility
Vapor Pressure
Octanol/Water Partition
pH
Stability
All
All
All
All
All
All
All
All
All
All
All
All
All
All
All
41741401
41741401
41741401
41741401
41741401
41741401
41741401
41741401
41741401
41741401
41741401
41741401
41741401,.
41741401
41741401
ECOLOGICAL EFFECTS
71-1A
71-2A
71-2B.
72-1A
72-1C
72-2A
72-3A
Acute Avian Oral - Quail/Duck
Avian Dietary - Quail
Avian Dietary - Duck
Fish Toxicity Bluegill
Fish Toxicity Rainbow trout
Invertebrate Toxicity
Estuarine/Marine Toxicity - Fish
88
C,E,F
C,E,F
C,E,F
C,E,F
C,E,F
C,E,F
C,E,F
41719501
41719502
41719503
41718801
41718802,41963503
41718803,42358701
00042556
. - • ' - .
-------
Data Supporting Guideline Requirements for the Reregistration of
Methylisothiazolinone
REQUIREMENT " ''
USE PATTERN
CITATIONfS)
72-3B Estuarine/Marine Toxicity -
Mollusk
72-3 C Estuarine/Marine Toxicity -
Shrimp
72-4A Early Life Stage Fish
72-4B Life Cycle Invertebrate
TOXICOLOGY ,
81-1 Acute Oral Toxicity - Rat
81-2 Acute Dermal Toxicity -
Rabbit/Rat
81 -3 Acute Inhalation Toxicity - Rat
81-4 Primary Eye Irritation - Rabbit
81-5 Primary Dermal Irritation -
Rabbit
' • ' i
81-6 Dermal Sensitization - Guinea
Pig .
82-1A 90-Day Feeding - Rodent
82-4 90-Day Inhalation - Rat
83-1A Chronic Feeding Toxicity -
Rodent
83-3A Developmental Toxicity - Rat
83-3B Developmental Toxicity - Rabbit
83-5 Combined Chronic Toxicity /
Carcinogenicity
84-2A Gene Mutation (Ames Test)
C,E,F 00042558
/ , • • -
C,E,F 00042559,00042557
C,E?F 42012201
C,E,F 41963502
All 00086091
All 00086092
All 41963501,42360901,
42360902
All 00086092
All 00086092
All 00144880
All
All
All
All
All
All
42810101
00148418
43140701
00078831
42311701
43140701
All 00078827,00096692,
•'• .. 00096693,00105044
89
-------
Data Supporting Guideline Requirements for the Reregistration of
Methylisothiazolinone
CITATION(S)
REQUIREMENT
USE PATTERN
84-2B " Structural Chromosomal
Aberration
84-4 • Other Genotoxic Effects
ENVIRONMENTAL FATE
160-5 Chemical Identity
161-1 Hydrolysis
162-1 Aerobic Soil Metabolism
163-1 Leaching/Adsorption/Desorption
168-1-SS Aqueous Availability
All 42538001
All 00130751,41875502
All 41741401
All 42578401,42681301
C 42086901
i • • . ,
,C,E,F 42086902
C,E 43478401
90
-------
GUIDE TO APPENDIX C
1. CONTENTS OF BIBLIOGRAPHY. This bibliography contains citations of all studies
considered relevant by EPA in arriving at the positions and conclusions stated elsewhere in
the Reregistration Eligibility Document. Primary sources for studies in this bibliography
have been the body of data submitted to EPA and its predecessor agencies in support of past
regulatory decisions. Selections from other sources including the published literature, in
those instances where they have been considered, are included.
2. UNITS OF ENTRY. The unit of entry in this bibliography is called a "study". In the case
of published materials, this corresponds closely to an article. In the case of unpublished
materials submitted to the Agency, the Agency has sought to identify documents at a level
parallel to the published article from within the typically larger volumes in which they were
submitted. The resulting "studies" generally have a distinct title (or at least a single subject),
can stand alone for purposes of review and can be described with a conventional
bibliographic citation. The Agency has also attempted to unite basic documents and
commentaries upon tihem, treating them as a single study.
3f IDENTIFICATION OF ENTRIES. The entries in this bibliography are sorted numerically
by Master Record Identifier, or "MRID number". This number is unique to the citation, and
should be used whenever a specific reference is required. It is not related to the six-digit
"Accession Number" which has been used to identify volumes of submitted studies (see
paragraph 4(d)(4) below for further explanation). In a few cases, entries added to the
bibliography late in the review may be preceded by a nine character temporary identifier.
These entries are listed after all MRID entries. This temporary identifying number is also
to be used whenever specific reference is needed.
4. FORM OF ENTRY. In addition to the Master Record Identifier (MRID), each entry consists
of a citation containing standard elements followed, in the case of material submitted to EPA,
by a description of the earliest known submission. Bibliographic conventions used reflect
the standard of the American National Standards Institute (ANSI), expanded to provide for
certain special needs.
a
Author. Whenever the author could confidently be identified, the Agency has chosen
to show a personal author. When no individual was identified, the Agency has
shown an identifiable laboratory or testing facility as the author. When no author or
laboratory could be identified, the Agency has shown the first submitter as the
author.
b. Document date. The date of the study is taken directly from the document. When
the date is followed by a question mark, the bibliographer has deduced the date from
the evidence contained in the document. When the date appears as (19??), the
Agency was unable to determine or estimate the date of the document.
91
-------
Title. In some cases, it has been necessary for the Agency bibliographers to create
or enhance a document title. Any such editorial insertions are contained between
square brackets.
Trailing parentheses. For studies submitted to the Agency in the past, the trailing
parentheses include (in addition to any self-explanatory text) the following elements
describing the earliest known submission:
(1) Submission date. The date of the earliest known submission appears
immediately following the word "received."
,'',"'' , ' '
(2) Administrative number. The next element immediately following the word
"under" is the registration number, experimental use permit number, petition
number, or other administrative number associated with the earliest known
submission.
(3) Submitter. The third element is the submitter. When authorship is defaulted
to the submitter, this element is omitted.
(4) Volume Identification (Accession Numbers). The final element in the
trailing parentheses identifies the EPA accession number of the volume in
which the original submission of the study appears. The six-digit accession
number follows the symbol "CDL," which stands for "Company Data
Library." This accession number is in turn followed by an alphabetic suffix
which shows the relative position of the study within the volume.
92
-------
MRID
BIBLIOGRAPHY
CITATION
00042556
00042557
00042558
00042559
00078827
00078831
00086091
00086092
Heitmuller, T. (1980) Acute Toxicity of Kathon WT to Sheepshead Minnows,
Cyprinodon variegatus: Report No. BP-80-3-53. (Unpublished study received Aug
28, 1980 under 707-128; prepared by EG&G, Bionomics, submitted by Rohm &
Haas Co., Philadelphia, Pa.; CDL:243239-A) , '
r- (
Heitmuller, T. (1980) Acute Toxicity of Kathon WT to Fiddler Crabs, Ucapugilator:
Report No. BP-80-3-52. (Unpublished study received Aug 28,1980 under 707-128;
prepared by EG&G, Bionomics,' submitted by Rohm & Haas Co., Philadelphia, Pa'
CDL:243238-A)
Hollister, T.A. (1980) Acute Toxicity of Kathone WT to EmbryoXarvae of Eastern
Oysters, Crassostrea virginica: Report No. BP-80-5-85. (Unpublished study received
Aug 28,1980 under 707-128; prepared by EG&G, Bionomics, submitted by Rohm
& Haas Co., Philadelphia, Pa.; CDL:243237-A)
Heitmuller, T. (1980) Acute Toxicity of Kathon WT to Pink Shrimp, Penaeus
duorarum: Report No. BP-80-3-51. (Unpublished study received Aug 28, 1980
under 707-128; prepared by EG&G, Bionomics, submitted by Rohm & Haas Co.,
Philadelphia, Pa.; CDL.-243240-A)
Scribner, H.E.; Melly, J.G.; Lohse, K.L. (1981); Kathon 886 MW; Microbial Mutagen
Test: Report No. 81R-96. (Unpublished study received Jul 8,1981 under 707-166;
submitted by Rohm & Haas Co., Philadelphia, Pa.; CDL:245555-C)
Weatherholtz, W.M.; Hoberman, A.; Durloo, R.S. (1980) Teratogenicity Study in
Rats: Kathon 886: Project No. 417-399. Final rept. (Unpublished study received Jul
8,1981 under 707-166; prepared by Hazleton Laboratories America, Inc., submitted.
by Rohm & Haas Co., Philadelphia, Pa.; CDL:245555-G)
Rohm and Haas Company (1977) Toxicity Data: Kathon 886 All-magnesium
Formulation: Report No. 77-38. (Unpublished study received on unknown date
under 707-129; CDL:233075-B)
Rohm and Haas Company (1976) Toxicity Data: F, MF or CT All-magnesium
Formulation: Report No. 76-56. (Unpublished study received Aug 8, 1977 under
707-129; CDL:233075-C)
93
-------
BIBLIOGRAPHY
MRID
CITATION
00096692 Scribner, H.E.; Melly, J.G.; Lohse, K.L. (1981) Kathon 886 MW; Microbial
Mutagen Test: Report No. 81R-96. (Unpublished study received Mar 17, 1982
under 707-166; submitted by Rohm & Haas Co., Philadelphia, Pa.;
CDL:247017-C)
00096693 Cifone, M.A.; Fisher, J. (1981) Mutagenicity Evaluation of TD-81-155 in the
Mouse Lymphoma Forward Mutation Assay: LBI Project No. 20989; Report No.
81RC-153. Final rept. (Unpublished study received Mar 17, 1982 under 707-166;
prepared by Litton Bionetics, Inc., submitted by Rohm & Haas Co., Philadelphia,
Pa.; CDL:247017-E) • .
00105044 Scribner, H.E.; Melly, J.G.; Lohse, K.L. (1981) Kathon 886 NAR Process;
Microbial Mutagen Test: Report No. 81R-97. (Unpublished study received Mar
17, 1982 under 707-166; submitted by Rohm & Haas Co., Philadelphia, Pa.;
CDL:247017-D)
00130751 Valencia, R. (1983) Drosophila Sex-linked Recessive Lethal Test on Kathon
Biocide: Laboratory Project No. 100; Rohm & Haas Project No. 82P-152. Final
rept. (Unpublished study received Aug 23, 1983 under 707-130; prepared by
Univ. of Wisconsin, Zoology Dept., submitted by Rohm & Haas Co.,
Philadelphia, PA; CDL: 251100-A)
00144880 Parsons, R. (1982) Delayed Contact Hypersensitivity Test of RH-573 and RH-886
ill.GuineaPigs: Report No. 79R-195. Unpublished study prepared by Rohm and
Haas Co. 52 p.
00148418 Hagan, J.; Baldwin, R. (1984) Kathon 886 MMPA Process: 13-Week Inhalation
Toxicity Study hi Rats; Report No. 82R-245. Unpublished study prepared by
Rohm and Haas Co. 267 p.
4^718801 Ward, T.; Boeri, R. (1990) Acute Flow Through Toxicity of Kathon 886 F Biocide
to the Bluegill Sunfish, Lepomis machcrochirus: Lab Project Number: 9002-RH:
89RC-0342. Unpublished study prepared by Resource Analysts Inc.,
• Envirosystems Div. 287 p.
41718802 Ward, T.; Boeri, R. (1990) Acute Flow Through of Kathon 886 Biocide to the
Rainbow Trout, Oncorhynchus mykiss: Lab Project Number: 9003-RH:
89RC-0343. Unpublished study prepared by Resource Analysts Inc.,
Envirosystems Div. 250 p.
94
-------
BIBLIOGRAPHY
MRID
CITATION
41718803 Ward, T.; Boeri, R. (1990) Acute Flow Through of Kathon 886 Biocide to the
Rainbow Trout, Oncorhynchus mykiss: Lab Project Number: 9001-RH:
89RC-0345. Unpublished study prepared by Resource Analysts Inc.,
Envirosystems Div. 209 p.
Derbyshire, R. (1990) Product Chemistry (of) Kathon 886F Microbiocide: Lab
Project Number: 1770.02. Unpublished study prepared by Rohm and Haas Co
518 p. ' ' .
Pedersen, C. (1990) Kathon 886 Biocide: 21-Day Acute Oral LD50 Study in
Bobwhite Quail: Lab Project Number: 90 QD148: 89RC-0339 Unpublished study
prepared by Bio-Life Associates, Ltd. 45 p.
Pedersen, C. (1990) Kathon 886 Biocide: 8-Day Acute Oral LC50 Study in
Bobwhite Quail: Lab Project Number: 90 QC148: 89RC- 0340- Unpublished study
prepared by Bio-life Associates, Ltd. 45 p.
Pedersen, C. (1990) Kathon 886 Biocide: 8-Day Acute Dietary LC50 Study in
Mallard Ducklings: Lab Project Number: 90 DC 145: 89RC-0341. Unpublished
study prepared by Bio-Life Associates, Ltd. 61. p.
Pant, K. (1990) Test for Chemical Induction of Unscheduled DNA Synthesis in Rat
- Primary Hepatocyte Cultures by Autoradiography: Kathon 886 MW Biocide: Final
Report: Lab Project No: 0159/5100: 90RC/168. Unpublished study prepared by
Sitek Research Labs. 29 p.
41963501 Wanner, F.; Hagan, J. (1991) Kathon 886F Biocide: Acute Inhalation Toxicity
Study in Rats: Lab Project Number: 91R-018: PROTOCOL No. 91P-018.
Unpublished study prepared by Rohm and Haas Co. 85 p.
41963502 Ward, T.; Boeri, R. (1991) Chronic Toxicity of Kathon 886 Biocide to the
Daphnid, Daphnia magna: Lab Project Number: 9005-RH: 89RC-0346.
Unpublished study prepared by Resource Analysts, Inc. 507 p.
41963503 Ward, T.; Boeri, R. (1991) Acute Flow Through Toxicity of Kathon 886 Biocide
to the Rainbow Trout, Oncorhynchus mykiss--14 Day Prolonged Test: Lab Project
Number: 9006-RH: 89RC-0348. Unpublished study prepared by Resource
Analysts, Inc. 306 p. . ' .
41741401
41719501
41719502
41719503
41875502
95
-------
BIBLIOGRAPHY
MRH)
CITATION
42086902
42311701
42358701
42360901
42360902
42538001
42578401
42681301
42810101
Wang, W. (1991) Adsorption and Desorption of carbon 14 |-RH-651 in Four Soils
and One Sediment: Lab Project Number: XBL 90024: RPTt)046: RH TECH.
34-91-09. Unpublished study prepared by XenoBiotics Labs, Inc. 86 p.
Thomas, T.; Solomon, EL; and O'Hara, G. (1992) Kathon Biocide: Oral (Gavage)
Developmental Toxicity Study in Rabbits: Lab Project Number: 91P-074.
Unpublished study prepared by Rohm and Haas Co. 206 p.
Jop, K. (1992) Kathon WT 1.5 Percent Biocide-Acute Toxicity to Cerlodaphnia
dubia under Static Conditions: Final Report: Lab Project Number: 92-404209:
91RC-0196: 86.0392-6152.132. Unpublished study prepared by Springborn Labs,
inc. 36 p.
Wanner, F.; Hagan, J. (1991) Kathon 886F Biocide Acute Inhalation Toxicity
Study in Rats: A Supplement: Lab Project Number: 91R-018A. Unpublished study
prepared by Rohm and Haas Co. 5 p.
Bernacki, H.; Hagan, J. (1992) Kathon 886F Biocide Acute Inhalation Toxicity
Study in Rats: A Supplement: Lab Project Number: 91R-018B. Unpublished study
prepared by Rohm and Haas Co. 5 p.
Gudi, R. (1992) Acute Test for Chemical Induction of Chromosome Aberation hi
Mouse Bone Marrow Cells in Vivo: Kathon 886 MW Biocide: Lab Project
Number: 0202-1541: 92RC-0054. Unpublished study prepared by SITEK Research
Lab. 65 p.
Marx, M.; Castle, S.; Shepler, K. (1992) Hydrolysis of (carbon 14)-RH-573 atpH
5, 7 and 9: Lab Project Number: 223W-1: 223W: 34-92-63. Unpublished study
prepared by Pharmacology and Toxicology Research Laboratory-West. 69 p.
Jalali-Araghi, K.; Shepler, K. (1993) Hydrolysis of (carbon 14)-RH-651 (the major
component of RH-886) at pH 5, 7 and 9: Lab Project Number: 225W-1: 225W:
34P-90-06: 34-93-07. Unpublished study prepared by Pharmacology and
Toxicology Research Laboratory-West. 134 p.
O'Hara, G.; DiDonato, L. (1982) Kathon 886 NAR: Three Month Rat Drinking
Water Study and One Generation Reproduction Study: Report No. 81R-162. Final
fept. (Unpublished study received Aug 23, 1983 under 707-130; submitted by
Rohm & Haas Co., Philadelphia, PA; CDL:251098-A)
96
-------
BIBLIOGRAPHY
MRID
CITATION
42840301 Weideborg, M. (1993) Toxicity Test Results with Acartia tonsa for the chemical
Kathon OM: Lab Project Number: 0-93007: 93-028: 93RC-1011. Unpublished
study prepared by Aquateam-Norwegian Water Technology Centre A/S. 27 p.
43140701 Quinn, D.; O'Hara, G.; Brown, W. (1994) Kathon Biocide: 24-Month Drinking
Water Chronic/Oncogenic Study in Rats: Final Report: Lab Project Number:
90P/149: 90R/149. Unpublished study prepared by Rohm and Haas Company
Toxicology Department. 5150 p.
43478401 Doshi, D. (1994) Aqueous Availability of Kathon WT from Treated Southern
Yellow Pine: Lab Project Number: 3122.00, Unpublished study prepared by
Rohm and Haas Co. and Hickson Corp. 325 p.
97
-------
98
-------
. PRQ1
UNITED STATES ENVIRONMENTAL PROTECTION AGENCY
WASHINGTON, D.C. 20460
OFFICE OF
PREVENTION. PESTICIDES
AND TOXIC SUBSTANCES
DATA CALL-IN NOTICE
CERTIFIED MAIL
Dear Sir or Madam:
This Notice requires you and other registrants of pesticide products containing the active ingredient
identified in Attachment 1 of this Notice, the Data Call-in Chemical Status Sheet to submit certain
product specific data as noted herein to the U.S. Environmental Protection Agency (EPA, the
Agency). These data are necessary to maintain the continued registration of your product(s)
containing this active ingredient. Within 90 days after you receive this Notice you must respond as
set forth in Section III below. Your response must state:
1.
2.
How you will comply with the requirements set forth in this Notice and its
Attachments 1 through 6; or -
Why you believe you are exempt from the requirements listed in this Notice and in
Attachments, Requirements Status and Registrant's Response Form, (see section
Why you believe EPA should not require your submission of product specific data
in the manner specified by this Notice (see section III-D).
99
-------
If you do not respond to this Notice, or if you do not satisfy EPA that you will comply with
its requirements or should be exempt or excused from doing so, then the registration of your
product(s) subject to this Notice will be subject to suspension. We have provided a list of all of
your products subject to this Notice in Attachment 2, Data Call-in Response Form, as well as a list
of all registrants who were sent this Notice (Attachment 6).
The authority for this Notice is section 3(c)(2)(B) of the Federal Insecticide, Fungicide and
Rodenticide Act as amended (FIFRA), 7 U.S.C. section 136a(c)(2)(B). Collection of this
information is authorized under the Paperwork Reduction Act by OMB Approval No. 2070-0107
and 2070-0057 (expiration date 03-31-99).
• • • • !'!' " "•""",, • . • • ' ' - ' ' j
This Notice is divided into six sections and six Attachments. The Notice itself contains
information and instructions applicable to all Data Call-in Notices. The Attachments contain
specific chemical information and instructions. The six sections of the Notice are:
Section I - Why You Are Receiving This Notice
Section II - Data Required By This Notice
Section III - Compliance With Requirements Of This Notice
Section IV - Consequences Of Failure To Comply With This Notice
Section V - Registrants' Obligation To Report Possible Unreasonable Adverse
Effects
Section VI- Inquiries And Responses To This Notice
The Attachments to this Notice are:
1 - Data Call-In Chemical Status Sheet
2 - Product-Specific Data Call-in Response Form
3 - Requirements Status and Registrant's Response Form
4 - EPA Batching of End-Use Products for Meeting Acute Toxicology Data
Requirements for Reregistration
5 - List of Registrants Receiving This Notice
6 - Cost Share and Data Compensation Forms
SECTION I. WHY YOU ARE RECEIVING THIS NOTICE
The Agency has reviewed existing data for this active ingredient and reevaluated the data
needed to support continued registration of the subject active ingredient. The Agency has
concluded that the only additional data necessary are product specific data. No additional generic
data requirements are being imposed. You have been sent this Notice because you have product(s)
containing the subject active ingredient.
• •: : • ' :"' ,.,'.. '••'.' .,••'•• T
SECTION II. DATA REQUIRED BY THIS NOTICE
II-A. DATA REQUIRED
100
-------
The product specific data required by this Notice are specified in Attachment 3, Requirements
Status and Registrant's Response Form. Depending on the results of the studies required in this
Notice, additional testing may be required.
-II-B. SCHEDULE FOR SUBMISSION OF DATA
You are required to submit the data or otherwise satisfy the data requirements specified in
Attachment 3, Requirements Status and Registrant's Response Form, within the time frames
provided.
II-C. TESTING PROTOCOL ,
All studies required under this Notice must be conducted in accordance with test standards
• outlined in the Pesticide Assessment Guidelines for those studies for which guidelines have been
established. , , ,
These EPA Guidelines are available from the National Technical Information Service
(NTIS), Attn: Order Desk, 5285 Port Royal Road, Springfield, Va 22161 (tel: 703-487-4650).
Protocols approved by the Organization for Economic Cooperation and Development
(OECD) are also acceptable if the OECD-recommended test standards conform to those specified
in the Pesticide Data Requirements regulation (40 CFR § 158.70), When using the OECD
protocols, they should be modified as appropriate so that the data generated by the study will
satisfy the requirements of 40 CFR § 158. Normally, the Agency will not extend deadlines for
complying with data requirements when the studies were not conducted in accordance with
acceptable standards. The OECD protocols are available from OECD, 2001 L Street, N.W.,
Washington., D-C. 20036 (Telephone number 202-785-6323; pax telephone number 202-785-
0350).
All new studies and proposed protocols submitted in response to this Data Call-in Notice
must be in accordance with Good Laboratory Practices [40 CFR Part 160.3(a)(6)].
II-D. REGISTRANTS RECEIVING PREVIOUS SECTION 3rcV2¥B^ NOTICES
ISSUED BY THE AGENCY
Unless otherwise noted herein, this Data Call-In does not in any way supersede or change the
requirements of any previous Data Call-In(s). or any other agreements entered into with the
Agency pertaining to such prior Notice. Registrants must comply with the requirements of all
Notices to avoid issuance of a Notice of Intent to Suspend their affected products.
SECTION III. COMPLIANCE WITH REQUIREMENTS OF THIS NOTICE
III-A. SCHEDULE FOR RESPONDING TO THE AGENCY
The appropriate responses initially required by this Notice for product specific data must
be submitted to the Agency within 90 days after your receipt of this Notice. Failure to adequately
101
-------
respond to this Notice within 90 days of your receipt will be a basis for issuing a Notice of Intent
to Suspend (NOIS) affecting your products. This and other bases for issuance of NOIS due to
failure to comply with this Notice are presented in Section IV-A and IV-B.
III-B. OPTIONS FOR RESPONDING TO THE AGENCY
The options for responding to this Notice for product specific data are: (a) voluntary
cancellation, (b) agree to satisfy the product specific data requirements imposed by this notice or
(c) request a data waiver(s).
A discussion of how to respond if you chose the Voluntary Cancellation option is presented
below. A discussion of the various options available for satisfying the product specific data
requirements of this Notice is contained in Section III-C. A discussion of options relating to
requests for data waivers is contained in Section III-D.
There are two forms that accompany this Notice of which, depending upon your response,
one or both must be used in your response to the Agency. These forms are the Data-Call-in
Response Form, and the Requirements Status and Registrant's Response Form. Attachment 2 and
Attachment 3. The Data Call-In Response Form must be submitted as part of every response to this
Notice. In addition, one copy of the Requirements Status and Registrant's Response Form must be
submitted for each product listed on the Data Call-In Response Form unless the voluntary
cancellation option is selected or unless the product is identical to another (refer to the instructions
for completing the Data Call-in Response Form in Attachment 2). Please note,that the company's
authorized representative is required to sign the first page of the Data Call-In Response Form and
Requirements Status and Registrant's Response Form (if this form is required) and initial any
subsequent pages. The forms contain separate detailed instructions on me response options. Do not
alter the printed material. If you have questions or need assistance in preparing your response, call
or write the contact person(s) identified in Attachment 1.
1. Voluntary Cancellation - You may avoid the requirements of this Notice by requesting
voluntary cancellation of your product(s) containing the active ingredient that is the subject of this
Notice, If you wish to voluntarily cancel your product, you must submit a completed Data Call-In
Response Form, indicating your election of this option. Voluntary cancellation is item number 5
on the Data Call-in Response Form. If you choose this option, this is the only form that you are
required to complete.
If you chose to voluntarily cancel your product, further sale and distribution of your
product after the effective date of cancellation must be in accordance with the Existing Stocks
provisions of this Notice which are contained in Section IV-C.
2. Satisfying the Product Specific Data Requirements of this Notice There are various
options available to satisfy the product specific data requirements of this Notice. These options are
discussed in Section III-C of this Notice and comprise options 1 through 6 on the Requirements
Status and Registrant's Response Form and item numbers 7a and 7b on the Data Call-In Response
102
-------
Form. Deletion of a use(s) and the low volume/minor use option are not valid options for fulfilling
product specific data requirements. •
3. Request for Product Specific Data Waivers. Waivers for product specific data are
discussed in Section III-D of this Notice and are covered by option 7 on the Requirements Status
and Registrant's Response Form. If you choose one of these options, you must submit both forms
as well as any other information/data pertaining to the option chosen to address the data
requirement. x
III-C SATISFYING THE DATA REQUIREMENTS OF THIS NOTICE ,
' • s •
, , If you acknowledge on the Data Call-In Response Form that you agree to satisfy the
product specific data requirements (i.e. you select item number 7a or 7b), then you must select one
of the six options on the Requirements Status and Registrant's Response Form related to data
production for each data requirement. Your option selection should be entered under item number
9, "Registrant Response." The six options related to data production are the first six options
discussed under-item 9 in the instructions for completing the Requirements Status and Registrant's
Response Form. These six options are listed immediately below with information in parentheses to
guide registrants to additional instructions provided in this Section. The options are:
(1) I will generate and submit data within the specified time frame (Developing Data)
(2) I have entered into an agreement with one or more registrants to develop data
jointly (Cost Sharing) "
• (3) I have made offers to cost-share (Offers to Cost Share)
(4) I am submitting an existing study that has not been submitted previously to the
Agency by anyone (Submitting an Existing Study)
(5) I am submitting or citing data to upgrade a study classified by EPA as partially '
acceptable and upgradeable (Upgrading a Study)
(6) I am citing an existing study that EPA has classified as acceptable or an existing
study that.has been submitted but not reviewed by the Agency (Citing an Existing
Study) -
Option 1. Developing Data — If you choose to develop the required data it must he in
conformance with Agency deadlines and with other Agency requirements as referenced herein and
in the attachments. All data generated and submitted must comply with the Good Laboratory
Practice (GLP) rule (4Q CFR Part 160), be conducted according to the Pesticide Assessment
Guidelines (PAG), and be in conformance with the requirements of PR Notice 86-5.
The time frames in the Requirements Status and Registrant's Response Form are the time
frames that the Agency is allowing for the submission of completed study reports. The noted
deadlines run.from the date of the receipt of this Notice by the registrant. If the data are not
submitted by the deadline, each registrant is subject to receipt of a Notice of Intent to Suspend the
affected registration(s).
103
-------
If you cannot submit the data/reports to the Agency in the time required by this Notice and
intend to seek additional time to meet the requirements(s), you must submit a request to the
Agency which includes: (1) a detailed description of the expected difficulty and (2) a proposed
schedule including alternative dates for meeting such requirements on a step-by-step basis. You
must explain any technical or laboratory difficulties and provide documentation from the
laboratory performing the testing. While EPA is considering your request, the original deadline
remains. The Agency will respond to your request in writing. If EPA does not grant your request,
the original deadline remains. Normally, extensions can be requested only in cases of
extraordinary testing problems beyond the expectation or control of the registrant. Extensions will
not be given in submitting the 90-day responses. Extensions will not be considered if the request
for extension is not made in a timely fashion; in no event shall an extension request be considered
if it is submitted at or after the lapse of the subject deadline.
Option 2. Agreement to Share in Cost to Develop Data — Registrants may only choose this
option for acute toxicity data and certain efficacy data and only if EPA has indicated in the
attached data tables that your product and at least one other product are similar for purposes of
depending on the same data. If this is the case, data may be generated for just pne
-------
agreement to be bound by binding arbitration as provided by FIFRA section 3(c)(2)(B)(iii) and
must not qualify this offer. The other registrant must also inform EPA of its election of an option
to develop and submit the data required by this Notice by submitting a Data Call-In Response
-Form and a Requirements Status and Registrant's Response Form committing to develop and
submit the data required by this Notice.
In order for you to avoid suspension under this option, you may not withdraw your offer to
share in the burdens of developing the data. In addition, the other registrant must fulfill its
commitment to develop and submit the data as required by this Notice. If the other registrant fails
to develop the data or for some other reason is subject to suspension, your registration as well as
that of the other registrant will normally be subject to initiation of suspension proceedings, unless
you commit to submit, and do submit the required data in the specified time frame. In such cases,
the Agency generally will not grant a time extension for submitting the data.
Option 4. Submitting an Existing Study — If you choose to submit an existing study in
response to this Notice, you must determine that the study satisfies the requirements imposed by
this Notice. You may only submit a study that has not been previously submitted to the Agency or
previously cited by anyone. Existing studies are studies which predate issuance of this Notice. Do
not use this option if you are submitting data to upgrade a study. (See Option 5).
You should be aware that if the Agency determines that the study is not acceptable, the
Agency will require you to comply with this Notice, normally without an extension of the required
date of submission. The Agency may determine at any time that a study is not valid and needs to
be repeated.
To meet the requirements of the DCI Notice for submitting an existing study, all of the
following three criteria must be clearly met:
a. You must certify at the time that the existing'study is submitted that the raw data
and specimens from the study are available for audit and review and you must
identify where they are available. This must be done in accordance with the
requirements of the Good Laboratory Practice (GLP) regulation, 40 CFR Part 160.
As stated in 40 CFR 160.3(j) " 'raw data' means any laboratory worksheets, records,
memoranda, notes, or exact copies thereof, that are the result of original
observations and activities of a study and are necessary for the reconstruction and
evaluation of the report of that study. In the event that exact transcripts of raw data
have been prepared (e.g., tapes which have been transcribed verbatim, dated, and
verified accurate by signature), the exact copy or exact transcript may be substituted
for the original source as raw data. 'Raw data' may include photographs, microfilm
or microfiche copies, computer printouts, magnetic media, including dictated ,
observations, and recorded data from automated instruments." The term
"specimens", according to 40 CFR 160.3(k), means "any material derived from a >
test system for examination or analysis."
105
-------
b. Health and safety studies completed after May 1984 must also contain all GLP-
required quality assurance and quality control information, pursuant to the
requirements of 40 CFR Part 160. Registrants must also certify at the time of
submitting the existing study that such GLP information is available for post-May
1984 studies by including an appropriate statement on-or attached to the study
signed by an authorized official or representative of the registrant.
c. You must certify that each study fulfills the acceptance criteria for the Guideline
relevant to the study provided in the FIFRA Accelerated Reregistration Phase 3
Technical Guidance and that the study has been conducted according to the
Pesticide Assessment Guidelines (PAG) or meets the purpose of the PAG (both
available from NTIS). A study not conducted according to the PAG may be
submitted to the Agency for consideration if the registrant believes that the study
clearly meets the purpose of the PAG. The registrant is referred to 40 CFR 158.70
Which states the Agency's policy regarding acceptable protocols. If you wish to
submit the study, you must, in addition to certifying that the purposes of the PAG
are met by the study, clearly articulate the rationale why you believe the study
meets the purpose of the PAG, including copies of any supporting information or
data. It has been the Agency's experience that studies completed prior to January
1970 rarely satisfied the purpose of the PAG and that necessary raw data are
usually not available for such studies.
If you submit an existing study, you must certify that the study meets all requirements of
the criteria outlined above.
If you know of a study pertaining to any requirement in this Notice which does not meet
the criteria outlined above but does contain factual information regarding unreasonable adverse
effects, you must notify the Agency of such a study. If such study is in the Agency's files, you
need only cite it along with the notification. If not in the Agency's files, you must submit a
summary and copies as required by PR Notice 86-5.
Option 5. Upgrading a Study — If a study has been classified as partially acceptable and
upgradeable, you may submit data to upgrade that study. The Agency will review the data
submitted and determine if the requirement is satisfied. If the Agency decides the requirement is
not satisfied, you may still be required to submit new data normally without any time extension.
Deficient, but upgradeable studies will normally be classified as supplemental. However, it is
important to note that not all studies classified as supplemental are upgradeable. If you have
questions regarding the classification of a study or whether a study may be upgraded, call or write
the contact person listed in Attachment 1. If you submit data to upgrade an existing study you
must satisfy or supply information to correct all deficiencies in the study identified by EPA. You
must provide a clearly articulated rationale of how the deficiencies have been remedied or
corrected and why the study should be rated as acceptable to EPA. Your submission must also
specify the MRID number(s) of the study which you are attempting to upgrade and must be in
conformance with PR Notice 86-5.
106
-------
Do not submit additional data for the purpose of upgrading a study'classified, as
unacceptable and determined by the Agency as not capable of being upgraded.
This option should also be used to cite data that has been previously submitted to upgrade a
study, but has not yet been reviewed by the Agency. You must provide the MRID number of the
data submission as well as the MRID number of the study being upgraded
The criteria for submitting an existing study, as specified in Option 4 above, apply to all
data submissions intended to upgrade studies. Additionally your submission of data intended to
upgrade studies must be accompanied by a certification that you comply with each of those criteria
as well as a certification regarding protocol compliance with Agency requirements.
1 ' " - •
Option 6. Citing Existing Studies -- If you choose to cite a study that has been previously
submitted to EPA, that study must have been previously classified by EPA as acceptable or it must
be a study which has not yet been reviewed by the Agency. Acceptable toxicology studies
generally will have been classified as "core-guideline" or "core minimum." For all other
disciplines the classification would be "acceptable." With respect to any studies for which you
wish to select this option you must provide the MRID number of the study you are citing and, if
the study has been reviewed by the Agency, you must provide the Agency's classification of the
study.
If you are citing a study of which you are not the original data submitter, you must submit a
completed copy of EPA Form 8570-31, Certification with Respect to Data Compensation
Requirements.
Registrants who select one of the above 6 options must meet all of the requirements
described in the instructions for completing the Data Call-In Response Form and the Requirements
Status and Registrant's Response Form, as appropriate.
III-D REQUESTS FOR DATA WAIVERS
If you request a waiver for product specific data because you believe it is
inappropriate, you must attach a complete justification for the request, including technical reasons,
data and references to relevant EPA regulations, guidelines or policies. (Note: any supplemental
data must be submitted in the format required by PR Notice 86-5). This will be the only
opportunity to state the reasons or provide information in support of your request. If the Agency
approves your waiver request, you will not be required to supply the data pursuant to section
3(c)(2)(B) of FIFRA. If the Agency denies your waiver request, you must choose an option for
meeting the data requirements of this Notice within 30 days of the receipt of the Agency's decision.
You must indicate and submit the option chosen on the Requirements Status and Registrant's
Response Form. Product specific data requirements for product chemistry, acute toxicity and
efficacy (where appropriate) are required for all products and the Agency would grant a waiver
only under extraordinary circumstances. You should also be aware that submitting a waiver
request will not automatically extend the due date for the study in question. Waiver requests
submitted without adequate supporting rationale will be denied and the original due date will
remain in force.
107
-------
IV. CONSEQUENCES OF FAILURE TO COMPLY WITH THIS NOTICE
IV-A NOTICE OF INTENT TO SUSPEND
The Agency may issue a Notice of Intent to Suspend products subject to this Notice due to
failure by a registrant to comply with the requirements of this Data Call-In Notice, pursuant to
FIFRA section 3(c)(2)(B). Events which may be the basis for issuance of a Notice of Intent to
Suspend include, but are not limited to, the following:
1.
2.
3.
4.
5.
7.
8.
Failure to respond as required by this Notice within 90 days of your receipt of this
Notice.
Failure to submit on the required schedule an acceptable proposed or final protocol
when such is required to be submitted to the Agency for review.
Failure to submit on the required schedule an adequate progress report on a study as
required by this Notice.
Failure to submit on the required schedule acceptable data as required by this
Notice.
Failure to take a required action or submit adequate information pertaining to any
option chosen to address the data requirements (e.g., any required action or
information pertaining to submission or citation of existing studies or offers,
arrangements, or arbitration on the sharing of costs or the formation of Task Forces,
failure to comply with the terms of an agreement or arbitration concerning joint
data development or failure to comply with any terms of a data waiver).
Failure to submit supportable certifications as to the conditions of submitted
studies, as required by Section III-C of this Notice.
Withdrawal of an offer to share in the cost of developing required data.
Failure of the registrant to whom you have tendered an offer to share in the cost of
developing data and provided proof of the registrant's receipt of such offer or
failure of a registrant on whom you rely for a generic data exemption either to:
a. inform EPA of intent to develop and submit the data required by this Notice
on a Data Call-In Response Form and a Requirements Status and
Registrant's Response Form:
b. fulfill the commitment to develop and submit the data as required by this
Notice; or
108
-------
9.
c. otherwise take appropriate steps to meet the requirements stated in this .
Notice, unless you commit to submit and do submit the required data in the
specified time frame.
Failure to take any required or appropriate steps, not mentioned above, at any time
following the issuance of this Notice.
IV-B. BASIS FOR DETERMINATION THAT SUBMITTED STUDY IS
UNACCEPTABLE
The Agency may determine that a study (even if submitted within the required time) is
unacceptable and constitutes a basis for issuance of a Notice of Intent to Suspend. The grounds for
suspension include, but are not limited to, failure to meet any of the following:
1. EPA requirements specified.™ the Data Call-In Notice or other documents incorporated
by reference (including, as applicable, EPA Pesticide Assessment Guidelines, Data
Reporting Guidelines, and GeneTox Health Effects Test Guidelines) regarding the design,
conduct, and reporting of required studies. Such requirements include, but are not limited
to, those relating to test material, test procedures, selection of species, number of animals,
sex and distribution of animals, dose and effect levels to be tested or attained, duration of
test, and, as applicable, Good Laboratory Practices.
2. EPA requirements regarding the submission of protocols, including the incorporation of
any changes required by the Agency following review.
3. EPA requirements regarding the reporting of data, including the manner of reporting,
the completeness of results, and the adequacy of any required supporting (or raw) data,
including, but not limited to, requirements referenced or included in this Notice or
contained in PR 86-5. All studies must be submitted in the form of a final report; a
preliminary report will not be considered to fulfill the submission requirement.
IV-C EXISTING STOCKS OF SUSPENDED OR CANCELLED PRODUCTS
EPA has statutory authority to permit continued sale, distribution and use of existing stocks
of a pesticide product which has been suspended or cancelled if doing so would be consistent with
the purposes of the Act.
The Agency has determined that such disposition by registrants of existing stocks for a
suspended registration when a section 3(c)(2)(B) data request is outstanding would generally not
be consistent with the Act's purposes. Accordingly, the Agency anticipates granting registrants
permission to sell, distribute, or use existing stocks of suspended product(s) only in exceptional
circumstances. If you believe such disposition of existing stocks of your product(s) which may be
suspended for failure to comply with this Notice should be permitted, you have the burden of
clearly demonstrating to EPA that granting such permission would be consistent with the Act. You
must also explain why an "existing stocks" provision is necessary, including a statement of the
109
-------
quantity of existing stocks and your estimate of the time required for their sale, distribution, and
use. Unless you meet this burden the Agency will not consider any request pertaining to the
continued sale, distribution, or use of your existing stocks after suspension.
!," |l j,',!1' ' ' ' ' '• '" '", 'II, '"•„,' i '',„ ' , , ' . ,'' , i
"ill I ' , ' ' ! '•',"" I, ' , « ' ,' ,' ' I ,
If you request a voluntary cancellation of your product(s) as a response to this Notice and
your product is in full compliance with all Agency requirements, you will have, under most
circumstances, one year from the date your 90 day response to this Notice is due, to sell, distribute,
or use existing stocks. Normally, the Agency will allow persons other than the registrant such as
independent distributors, retailers and end users to sell, distribute or use such existing stocks until
the stocks are exhausted. Any sale, distribution or use of stocks of voluntarily cancelled products
containing an active ingredient for which the Agency has particular risk concerns will be
determined on case-by-case basis.
Requests for voluntary cancellation received after the 90 day response period required by
this Notice will not result in the Agency granting any additional time to sell, distribute, or use
existing stocks beyond a year from the date the 90 day response was due unless you demonstrate to
the Agency that you are in full compliance with all Agency requirements, including the
requirements of this Notice. For example, if you decide to voluntarily cancel your registration six
months before a 3 year study is scheduled to be submitted, all progress reports and other
information necessary to establish that you have been conducting the study in an acceptable and
good faith manner must have been submitted to the Agency, before EPA will consider granting an
existing stocks provision.
SECTION V. REGISTRANTS' OBLIGATION TO REPORT POSSIBLE
UNREASONABLE ADVERSE EFFECTS
Registrants are reminded that FIFRA section 6(a)(2) states that if at any time after a
pesticide is registered a registrant has additional factual information regarding unreasonable
adverse effects on the environment J>y the pesticide, the registrant shall submit the information to
the Agency. Registrants must notify the Agency of any factual information they have, from
whatever source, including but not limited to interim or preliminary results of studies, regarding
unreasonable adverse effects pn man or the environment. This requirement continues as long as
the products are registered by the Agency.
SECTION VI. INQUIRIES AND RESPONSES TO THIS NOTICE
If you have any questions regarding the requirements and procedures established by this
Notice, call the contact person(s) listed in Attachment 1, the Data Call-In Chemical Status Sheet.
110
-------
All responses to this Notice (other than voluntary cancellation requests and generic data
exemption claims) must include a completed Data Call-in Response Form and a completed
Requirements Status and Registrant's Response Form (Attachment 2 and Attachment 3 for product
specific data) and any other documents required by this Notice, and should be submitted to the
contact person(s) identified in Attachment 1. If the voluntary cancellation or generic data
exemption option is chosen, only the Data Call-in Response Form need he submitted
The Office of Compliance Monitoring (OCM) of the.Office of Pesticides and Toxic
Substances (OPTS), EPA, will be monitoring the data being generated in response to this Notice.
Sincerely yours,
SisA. Ro/si,pirecto?
'Special Review and
Reregistration Divisifc
Attachments
1 -
.2 -
3 -
4 -
5 -
6 -
Data Call-In Chemical Status Sheet
Product-Specific Data Call-in Response Form
Requirements Status and Registrant's Response Form
EPA Batching of End-Use Products for Meeting Acute Toxicology Data
Requirements for Reregistration
List of Registrants Receiving This Notice
Cost Share and Data Compensation Forms and the Confidential Statement of
Formula Form
111
-------
112
-------
METHYLISOTHIAZOLINONE DATA CALL-IN, CHEMICAL STATUS SHEET
INTRODUCTION
. You have been sent this Product Specific Data Call-In Notice because you have product(s)
containing methylisothiazolinone.
This Product Specific Data Call-in Chemical Status Sheet rnntaing an ™,^,Hy rf data
required by this notice, and point of contact for inquiries pertaining to the reregistration of
methylisothiazolinone. This attachment is to be used in conjunction with (1) the Product Specific
Data Call-in Notice, (2) the Product Specific Data Call-in Response Form (Attachment 2), (3) the
Requirements Status and Registrant's Form (Attachment 3), (4) EPA's Grouping of, End-Use
Products for Meeting Acute Toxicology Data Requirement (Attachment 4), (5) the EPA Acceptance.
Criteria (Attachment 5), (6) a list of registrants receiving this DCI (Attachment 6) and (7) the Cost
Share and Data Compensation Forms in replying to this Methylisothiazolinone Product Specific
Data Call-In (Attachment 7). Instructions and guidance accompany each form.
DATA REQUIRED BY THIS NOTICE
The additional data requirements needed to complete the database for methylisothiazolinone
are contained in the Requirements Status and Registrant's Respnn.^ Attachment 3. The Agency has
concluded that additional data on methylisothiazolinone are needed for specific products. These data
are required to be submitted to the Agency within the time frame listed. These data are needed to
folly complete the reregistration of all eligible methylisothiazolinone products.
INQUIRIES AND RESPONSES TO THIS NQTTCF.
If you have any questions regarding this product specific data requirements and procedures
established by this Notice, please contact Barbara Briscoe at (703) 308-8177.
All responses to this Notice for the Product Specific data requirements should be submitted
to: - .
Barbara Briscoe -• \. . ,
Chemical Review Manager Team 81
Product Reregistration Branch
Special Review and Reregistration Branch 7508C
Office of Pesticide Programs
U.S. Environmental Protection Agency
Washington, D.C. 20460
RE: Methylisothiazolinone
113
-------
INSTRUCTIONS FOR COMPLETING THE DATA CALL-IN RESPONSE FORM FOR
PRODUCT SPECIFIC DATA
, ' • .' •
Item 1-4. Already completed by EPA.
Item 5. If you wish to voluntarily cancel your product, answer "yes." If you choose this
option, you will not have to provide the data required by the Data Call-In Notice and
you will not have to complete any other forms. Further sale and distribution of your
product after the effective date of cancellation must be in accordance with the
Existing Stocks provision of the Data Call-In Notice (Section IV-C).
Item 6. Not applicable since this form calls in product specific data only. However, if your
product is identical to another product and you qualify for a data exemption, you
must respond with "yes" to Item 7a (MUP) or 7B (EUP) on this form, provide the
EPA registration numbers of your source(s); you would not complete the
"Requirements Status and Registrant's Response" form. Examples of such products
include repackaged products and Special Local Needs (Section 24c) products
which are identical to federally registered products.
Item 7a. For each manufacturing use product (MUP) for which you wish to maintain
registration, you must agree to satisfy the data requirements by responding "yes."
Item 7b. For each end use product (EUP) for which you wish to maintain registration, you
must agree to satisfy the data requirements by responding "yes." If you are
requesting a data waiver, answer "yes" here; in addition, on the "Requirements
Status and Registrant's Response" form under Item 9, you must respond with Option
7 (Waiver Request) for each study for which you are requesting a waiver. See Item
6 with regard to identical products and data exemptions.
Items 8-11. Self-explanatory.
NOTE: You may provide additional information that does not fit on this form in a signed
letter that accompanies this form. For example, you may wish to report that your
product has already been transferred to another company or that you have already
voluntarily canceled this product. For these cases, please supply all relevant details
so that EPA can ensure that its records are correct.
114
-------
H
U-4
O
r-
•
cu
0
U
EH
EM
.
^s
Q
/
' rH
ro
o
p- r-
o in co
HO 0)
O 0 J-|
TJ , i 1 -rt
0) O O G,
O o o H
rl OJ CN
Oi • CO
<, O ^
p . i a
[n O 0
O ^D
'(L) ^ H
4-1 0 CO
O oj B
M O
PJ • ft
o co
CO • P4
-U Q
d B
0) - l-l
d O j
O 4J J
J-! tJ) rij . •
">-H
H CQ H-
M !S Q
QJ
JJ
(C
-U
CO
•a
<»
-H
*
0
to
-rt
x:
jj
§
TJ
0)
jj
03
(!)
Cr1
'03
O
•rt
JJ
(0
E
iH
O
C
•rt
t XI 'D1 in
CQ 4-J JJ 0) JJ
•H M Erf CQ
•rt , C = -H
JJ JJ O CT>
O RJ TJ 0)
3 CQ CQ 0) Pi
TJ JJ rH
•O O C -U TJ =
?H JJ 0) -rt C
Qi E JJ (0 0)
0) Q) C CO
>* (1) JH 0) to C
S !H -H 3 O
Di 3 E JJ QJ
• OJ O1 M (0 CQ
fC 0) 'O JJ 0)
r- M M n-i co erf
O TJ
•H OJ.TJ
V) JJ 0)
0) (0 rH
C O JJ
0) -rt -rt
>i ;rt Q) JH 0)
3 C 0)
nj co -rt p< jj
u QJ ra
H -HO
E C JJ O rl
rt O U }H 0)
(0 -H (C 3 XJ
rH JJ. O E
O Q. 0) CQ 3
E 0) JJ 6
rex x; a
H C JJ O
M -rt -rt
as (0 E JJ
• jj jj o ai
aJ to Xt n JH
vo Q O 4-t JJ
i i
n c
O -H 3
JJ CQ Ol M
•H 0) O
CO JJ
•H JJ C
S iH U O X
CO 3 -rt r-l
H O Ti JJ 'H
c o to n
• (0 • S-i J-l (0
JJ
o •
3 C'
O -rt
J-( JJ
* s
g .3 j
• . 01
•* 0!
L_ __ _J _
t .
t
. ,
. , '
I .
'
• .
^ '.
j^l
i .
B •'....
g • '
^
OJ
JJ
ffl
Q
JJ
CO QJ
JJ £ '
rH O
O ^
TJ -rt
C
10 -
, c
U '
O
U (U
10
rH JJ JJ
rH OS (0
OJ 4J.
TJ C 0)
. C -rt CO
as TJ a)
as H
H rH 0) '
o CQ erf
UH -rt
E TS
CO (D
•rt }H H
x: o -ri
0) O
cm x:
O rH JJ
at 3
i CQ
E '&! >,
WC-' C
JJ -«H- 3 0(
C S as a
11 « 1
JJ rH
JJ C CO O
CO 10 U
Certification
ertify that the
cknbwledge that
both under appli
nature and Title
U 10 Dl
CO M M O CO
S
XI
3
Z
CD
O
S
*
:
-------
INSTRUCTIONS FOR COMPLETING THE REQUIREMENTS STATUS AND
REGISTRANT'S RESPONSE FORM FOR PRODUCT SPECIFIC DATA
Item 1-3 Completed by EPA. Note the unique identifier number assigned by EPA in Item
3. This number must be used in the transmittat document for any data
submissions hi response to this Data Call-In Notice.
Item 4. The guideline" reference numbers of studies required to support the product's
continued registration are identified. These guidelines, in addition to the
requirements specified in the Notice, govern the conduct of the required studies.
>fpte that series,61 and 62 in product chemistry are now listed under 40 CFR 158.155
through 158.180, Subpart C.
Item 5. The study title associated with the guideline reference number is identified.
Item 6. The use pattern(s) of the pesticide associated with the product specific requirements
is (are) identified. For most product specific data requirements, all use patterns are
covered by the data requirements. In the case of efficacy data, the required studies
only pertain to products which have the use sites and/or pests indicated.
, ! '' .
Item 7. The substance to be tested is identified by EPA. For product specific data, the
product as formulated for sale and distribution is the test substance, except in rare
cases.
Item 8. The due date for submission of each study is identified. It is normally based on 8
months after issuance of the Reregistration Eligibility Document unless EPA
determines that a longer time period is necessary.
Item 9. Enter only one of the following response codes for each data requirement to
show how you intend to comply with the data requirements listed in this table.
Fuller descriptions of each option are contained in the Data Call-in Notice.
1. I will generate and submit data by the specified due date (Developing Data). By
indicating that I have chosen this option, I certify that I will comply with all the
requirements pertaining to the conditions for submittal of this study as outlined hi the
Data Call-In Notice. By the specified due date, I will also submit: (1) a completed
''Certification With Respect To Data Compensation Requirements" form (EPA
Form 8570-29) and (2) two completed and signed copies of the Confidential
Statement of Formula (EPA Form 8570-4).
2. I have entered into an agreement with one or more registrants to develop data jointly
(Cost Sharing). I am submitting a copy of this agreement. I understand that this
option is available only for acute toxicity or certain efficacy data and only if EPA
indicates in an attachment to this Notice that my product is similar enough to another
116
-------
5.
product to qualify for this option. I certify that another party in the agreement is
committing to' submit or provide the required data; if the required study is not
submitted on time, my product may be subject to suspension. By the specified due
date, I will also submit: (1) a completed "Certification With Respect To Data
Compensation Requirements" form (EPA Form 8570-29) and (2) two completed
and signed copies of the Confidential Statement of Formula (EPA Form 8570-4).
I have made offers to share in the cost to develop data (Offers to Cost Share). I
understand that this option is available only for acute toxicity or certain efficacy data
and only if EPA indicates in an attachment to this Data Call-In Notice that my
product is similar enough to another product to qualify for this option. I am
submitting evidence that I have made an offer to another registrant (who has an
obligation to submit data) to share in the cost of that data. I am also submitting a
completed "Certification of Offer to Cost Share in the Development Data" form.
I am including a copy of my offer and proof of the other registrant's receipt of that
offer. I am identifying the party which is committing to submit or provide the
required data; if the required study is not submitted on time, my product may be
subject to suspension. I understand that other terms under Option 3 in the Data Call-
in Notice (Section HI-C.l.) apply as well. By the specified due date, I will also
submit: (1) a completed "Certification With Respect To Data Compensation
Requirements" form (EPA Form 8570-29) and (2) two completed and signed
copies of the Confidential Statement of Formula (EPA Form 8570-4).
By the specified due date, I will submit an existing study that has not been submitted
previously to the Agency by anyone (Submitting an Existing Study). I certify that
this study will meet all the requirements for submittal of existing data outlined in
Option 4 in the Data Call-in Notice (Section III-C.l.) and will meet the attached
acceptance criteria (for acute toxicity and product chemistry data). I will attach the
needed supporting information along with this response. I also certify that I have
determined that this study will fill the data requirement for which I have indicated
this choice. By the specified due date, I will also submit a completed "Certification
With Respect To Data Compensation Requirements" form (EPA Form 8570-29)
to show what data compensation option I have chosen. By the specified due date, I
will also submit: (1) a completed "Certification With Respect To Data
Compensation Requirements" form (EPA Form 8570-29) and (2) two completed
and signed copies of the Confidential Statement of Formula (EPA Form 8570-4).
By the specified due date, I will submit or cite data to upgrade a study classified by
the Agency as partially acceptable and upgradable (Upgrading a Study). I will
submit evidence of the Agency's review indicating that the study may be upgraded
and what information is required to do so. I will provide the MRID or Accession
number of the study at the due date. I understand that the conditions for this option
outlined Option 5 in the Data Call-In Notice (Section III-C.L) apply. By the
specified due date, I will also submit: (1) a completed "Certification With Respect
117
-------
To Data Compensation Requirements" form (EPA Form 8570-29) and (2) two
completed and signed copies of the Confidential Statement of Formula (EPA
Form 8570-4).
6. By the specified due date, I will cite an existing study that the Agency has classified
as acceptable or an existing study that has been submitted but not reviewed by the
Agency (Citing an Existing Study). If I am citing another registrant's study, I
understand that this option is available only for acute toxicity or certain efficacy data
and only if the cited study was conducted on my product, an identical product or a
product which EPA has "grouped" with one or more other products for purposes of
depending on the same data. I may also choose this option if I am citing my own
data. In either case, I will provide the MRID or Accession number(s) for the cited
data on a "Product Specific Data Report" form or in a similar format. By the
specified due date, I will also submit: (1) a completed "Certification With Respect
to Data Compensation Requirements" form (EPA Form 8570-29) and (2) two
completed and signed copies of the Confidential Statement of Formula (EPA
Form 8570-4).
7. I request a waiver for this study because it is inappropriate for my product (Waiver
Request). I am attaching a complete justification for this request, including technical
reasons, data and references to relevant EPA regulations, guidelines or policies.
[ISfote: any supplemental data must be submitted in the format required by P.R.
Notice 86-5]. I understand that this is my only opportunity to state the reasons or
provide information in support of my request. If the Agency approves my waiver
request, I will not be required to supply the data pursuant to Section 3(c)(2)(B) of
FIFRA. If the Agency denies my waiver request, I must choose a method of meeting
the data requirements of this Notice by the due date stated by this Notice. In this
case, I must, within 30 days of my receipt of the Agency's written decision, submit
a revised "Requirements Status and Registrant's Response" Form indicating the
option chosen. I also understand that the deadline for submission of data as specified
f>y the original data call-in notice will not change. By the specified due date, I will
also submit: (1) a completed "Certification With Respect To Data Compensation
Requirements" form (EPA Form 8570-29) and (2) two completed and signed
copies of the Confidential Statement of Formula (EPA Form 8570-4).
Items 10-13. Self-explanatory.
NOTE: You may provide additional information that does not fit on this form in a signed
. letter that accompanies this form. For example, you may wish to report that your
product has already been transferred to another company or that you have already
voluntarily canceled this product. For these cases, please supply all relevant details
so that EPA can ensure that its records are correct.
118
-------
CN
(
. H
(
. c
c
ft
o
o
EH
PH
OH
Q
en
CJ*
iH
O
p- r>
o in co
HO cy
o o Jq
Ti 1 1 -H
aj o o a
> c-c< x
O O c5 p]
r) (MM
& r-f
ft • OJ
f$ Q r>
= s P
E 2-4
•u en a
o s a
t. o «c
^
:>, w
O CO
'g .8'
tn ft
«1 CO
o
-H CO
4-> 0 •»
(D ^ S
4-> 0 2
O CN K
r \ i i
rH O '
-u Q PS
fi
£ fl §
fl O rtj
O 4-)
^ CTl CO
•H a p,
> -H EH
SH rCj
CO
(U JJ
0). 0 M
O Q,
O« Cd
H
OSOBOUOJ
01
I
JJ
CO
LO
C 'Jj'
-H G
i— ) (U
, -r-1 ^ O rH IM O J.1
rHjJjJOI-IISOX: -H-
fSS^^ScSS &
^ gjjia oca OS cs S
, "O C C-rfUjJrH CO ^
JJOW-H-r*COO rH O
E JJa3H>rai4-H-H.H 15 >. c
a) O-HT30C03E<«JJ o jj w
u 3 M o o 3 a -H -H >, u -H -H >,
° CKQ a oISS8SoQaw
tS
^
ftS rQ
1 ^-* ^-^ Csl CO
11 1 1 1 I I 1 1 1 1 1
^O VD ^D ^O VO VD VO *^D ^D V^) LD LO
jj
Q
M
rH
T-I
»
OJ
• C
JJ E
0) G
•-I O
Ctj CO •
I'd
U 0,
*O -H
(0 -
.s
(U -H
flj
3.^*
U
O Q)
(0 «H
J2 '
U) J2
.3 W '
4J G
,
O E
x; jj
o c
JJ 'E
jj a> cu
15 JJ >
15 -H
iH JJ JJ
rH CQ 15
15 JJ
•e £' S
C -H CO
15 TJ Ol
E tu a
o ra a.
made on this f
gly false, or mi
y's Authorized
to c • c
JJ -H S 15
c s « a
cu o .H s
EC O '
a) .« « o
JJ rH
• 15 x ja 4-1
JJ C 15 O
CO 15 U
-H a)
a) JJ rH rH
c x; 15 a jj
o jj x; a -H
H JJ rC CH
JJ JJ
o x; en a) c'
H JJ T3 13 15
« 0) C
H >, rH 3 ai
jj uj s n
Jj -H 0 X 3
a> jj c jj jj
O r-l Ji O 15
a> o ja c
• U 16 Ol
0 U -H '
H IH M O CO
aj
X!
1 •
a>
c
o
Oj
ro
H
.
u
O
(6
JJ
C
0
0.
I
o
0
M-l
O
OJ
e
&
ca
r-l
-------
OJ
o
OJ
0)
tn
m
CM
^H
CM
O
u
EH
Ct»
Pi
P
a\
a\
o
r* o
O tft S)
O O M
•a i i -H
S 00 Q.
> t* r- x
o o o w
i, "^ .-i
§ o >
*' * S
B co a
o s* a
£ 5 <
S^ J£]
0 CO
C B
Q) O
tn cn
rj {2
o
•H CQ
4J O •»
O ^D EH
CD ^* ^H"
4-) O S
O 05 K
CM • CO
O H
rH O
4-> P S
£j
0) - P
ECS
rHI /™\ *^f"
C O flj
O 4->
•M CD CQ
•H C p
c5 rt i^
pq CQ EH
OS CQ
CQ IS
EH
CQ S
T) S
0) H
4-> P
•H O!
g §
4
1
CO
1
i
>
T3
j
m
O
3
y
j
c
>
•H
jj
|
3
O
4
•H
1)
J
B
19
to
••
H
LJ
3
n
•H
*o
at
g
u
(!)
JJ
a
5
>,
H
3
41
a
a
•a
(d
41
u
el
m
4)
cu
i;
c
•H
5 &
JJ fl3
c a
•H CQ
^ 0)
a g
H C
o
yj
Q] fH
S-
jj tn
41 JJ
to 41
a 41
m £
rH 10
a
i 1
0 -H
M J.
1!
CO fl
S G
M r>
g
S
O §
hi
*
_ H P
?s*
S g
H EH 2
•0 r=J S
a p
i O
rM 53
e 4-1
m d) •
s S tn
"§ ^
(3 fv{
O3
S o CM
o n P3
O)
O
0
CO 0
CQ O
M o
01 !>< ftl
•o § p X
S CM ril txl
S
13 ^~*
10 U H -
C n r . i t
I— 1 tH f~l
^ CM CQ U
g co S S
-
JJ
c
S
jj
CQ 0)
•H m
Sfg
of a
03
• OJ
a\ erf
1 i
- 2
CO fc
(U
CO (Q
a> u
r- 03
. Use
attern
\D CU
= rO
fl) JJ
i-l SH na
O> O
O &
CU CJ
H
1« 0:0^0 OO t-3
0)
jj
•rH
ra
m
QJ
C JJ
•H C
rH 0)
0) E
T3 0)
•H M H
3 -H (U
0 &•§
^S i
o o o o o o o o
g g g g g g g g
00 CO 00 OO CO 00 00 00
CM CM CM CM CM ;CM CM CM
CM CM CM CM CM CM CM CM
S S.S S 2S-.S-S
OOOOOOOQ
^y !3 ^ Sj ^j |2 t^l ri '
^4 ^4 ^< '^4 P^4 *^4 ^4 ^4,
ID 1-3 ID h) hj hs'hj 'o
M M M M M M M HH
ffi ;K ffi ffi . ffi 5J K-K
o p o o o o o a
pri ,Kj [j[ ')*TJ ' pTj pr;.j pTj , p£.j
[JL.] EJtl K pj3 W pcj |xl fol
; ri] rrf!l rfl -rfj. ^ ^-Q ^ f^I
'''..' , - ' ' • • ,• '
0 . rH M. CO CO ..- iR
•s i , . -a i .-;
-m 0 4) _O ffl
^H 3 X JJ T3 »-j
tn 6 JJ o A: ; 9
41 4) -H . , OJ 'IB p
.4} >i M (0 ^ 0-
M 0 & -H ffi S 0 , 1
O -rt, «H J-> ." _ O1 ,.
*H Ol .i-H -ri ' W >i •-•"» C . ,:rt :t*
m C "rl J3 JJ . >H O H w
-H 'H J2 . OS ' 41 -H -H -H JJ :X
UN ffl Tl . Dl g fj. g , ,g . >
TO -H 10 & O 10 M H : 41 :€
X f-< X JJ -^ '-j O -H X
o K.; u co- > .s u a c
• . . " , '«
1 ' i',1.
.
^^ LO vo r^ co 0*1 c^ tH
tH r-1 rH H rH rH ca OJ
1 1 1 1 1 III
ro ro ro ro co oo ro ro
u> w> vo «> vo v*>. VD «>
CQ CQ CQ CQ CQ CQ
O O O Oi O O
;s: g : ess E
co: cO oo oo co oo
CM: CM CM CM CM :CM
•$•£?, \-^.-^.-^.
CM CM CM CM CM CM
s s s s s s
o o o o o o
*3 S ' r3 S IS 2*
'§;S ; jSS^
MM M H M :M
l__4 ^_,| ' f__{ |_H h-pH |-|H
rn rr] jTj p_j p.) ^
O O • O O O ;O
fo j pr^ pT] [-rj jxi {Xi
.pq. pa pq pq H :w
p p p p p p
a o o a o a
fQ CQ CQ pQ CQ g
rf* ^ 1 ,fd C ,.;
jj ; '^1 O •
; jj ' -H , I ', -H ' . '•
a , o ;c JJ
•' }j • 4J -H O (0
, ,|. RJ « -H JJ CJ.
; .>, M O 4J -K ,O
" ai. ^x. jj to M -rf
O - »H C -H -H RJ
•H .^3 O . I-l N;
.« ,.^l --H fr rH :-H
O- 'fO; JJ *" • (0 • ' JJ
• Jj- rH -V< • (0 • .' " E • lir^'
:'. :•;• rt , • -H , ;(U; M to
, M • Q) -H: C tn '
, ;O:' 13 >'O "H -. ,>» >««
1 ' ' ''ri< r4 .M r*H
3 3 -U 3 -H -H .H
O' U ,: O M i-4 OJ
.< < . . . < Oi & O
i i ii i i
rH T-l rH ,i-l H Hi
CO CO CO CO CO CO
(U
Jj
g.
4)
en
a
to
-H
X
JJ
c
o
c
o
jj
0 •
c ~a
-rt C
JJ. HI-
B)
10 a
•H
JJ 10
(0 -H
O
-H C
w o
•H -H
JJ JJ
n ca
41 O
O -H
1M
a) -H
jj jj
10 H
O 4)
•H U
•D
C «•!
•rt O
O JJ
JJ X
4)
r-1 JJ
US
•H iH
JJ i-H
c5 ••
hH —
-------
CN
«rA
^
H
'(U
. (T
f
,.
><
a
_^
p
U
H
fe
<:
fU
Q
United States Environmental Protection Agency
Washington, D. C. 20460
8
FNOTES AND KEY DEFINITIONS FOR GUIDELINE REQUIREME
cr»
o
s
Case # and Name: 3092 Methylisothiazolinone
0) JJ
JJ C
•H (U
o e
O -H
JJ §•
•H Q)
1 h S!
,3 «j -H
W .JJ JJ
(0 O
4J 73 nj
§•>,=
G (U
TJ (0 ^
fl) 3
end-use product; provided formulators purchase their active ingredient (s) from a r
NOTE: If a product is a 100 percent repackage of another registered product, regis
end-use product;TGAI = technical grade of the active ingredient; PAI = "pure" acti
U • rH
JJ qj
0. U 0
H 3 -rl
*o Ctt
-OS
JJ JH JJ
o a
3 II
•a TJ
o ID a.
^ CO Kl
a a EH
w en jj t)
3 c is
C -rl C Vf
18 C -rl
S -H
= cfl T3 JJ
II JJ (US
rl -rl (U
Oj (D tw -H
s a -H 13
JJ 0}
;• ffl C SH
>i JJ 0) Dl
.0) us -a c
M TJ -H -ri
o
o
s •••'•
3 ' rH
,o ni
.H
TU JJ
o c
«H T! ,
C -H '
o ro
C , n
• U }H .
- -rl 4J rl
JJ CO O
to a) o "
woe s
o
fa 1-3 o ta
:s -
o
a.
CO
£8.
a <£ •
o
in CO
1?
restrial food feed crop C - Terrestrial nonfood crop D - Aquatic food crop
atic nonfood residential H - Greenhouse food crop I -- Greenhouse nonfoo
oor food - M - Indoor nonfood N - Indoor Medical
referenced in column two (5. Study Title) of the REQUIREMENTS STATUS AND REGISTRAR
U 3 T3 0)
i i i ro'
QJ
m o >j jj
§
iH [Jl
a c
•H -H
rl S
JJ O
8-3 3
^ *Cf rl O
o c o «j
M 0
•O -O 0)
O -C JJ X
O O 3 EH
" 1 H
E
HI
6
IS
4
Bi
6
'O
1
C5 S
tf) $-4 O
tn o ri
rH q-l £
in ^D a)
I— 1 rH
co O
•• rH
01 * O
C co
O fi
-H •* •
JJ ^. CO
o w to
(U l rH '
W i-t -k
tn —
C 13
•H CO G
O ID
.-H U -*
rH O —
O to «
»M a i
a) Di us
42 G —
JJ -H
fH 0]
C 3 JJ
•iH JJ -H
* g'.|
ntity, composition, analysis, and certification of ingredients are detailed- furthe:
}; *158.160, 158.162, and 158.165 for description of starting materials arid manuf;
(61-3); *158.170 for preliminary analysis (62-1); *158.175 for certification of 1;
0) .H •
13 i to
ID -H
JJ — JJ
O -rT
3 C ^
13 O 3
o -H a
.^ -u e
a -H -H
to
O O MH
jj a o —
tn o c .1
G O O 03
-H *H ^D
C TJ JJ — -
•H C (TJ
(0 (U E to
JJ rl TJ
^ >i O O
0> JJ IH 42
-P, -H • jj
JJ «H tt)
W C O E
JJ ,
3 T3 O rH
D1 O 01 OS
.
G
(1)
g
fl)
Q>
S4
^
S
(0
c
o
•
3 -H
(C ' O
C JJ <
- O -- G
0) 0) (U
JJ ' rl -0
C cn nj
.—1 r« « •
Eull scale production and an experimental use permit is sought, a discussion of un:
Le-. ,
, .whether produced by an integrated system or not, the technical grade of Active Ii
sdlated, -a statement of composition of the practical equivalent of the technical gi
a case-by-case basis. ...
Inert ingredients in products proposed for experimental use.
jible with, water. . '
Lng or reducing agent. " ' ;
-e liquids. -
.osive . ' - • " .
J3CU-HC }H N .Q a
T3-H rljaTJM-1 CO-H VI
S 2j ° . 0) -H x 3 >,
rBCUo'-Hlo'^^'firH
^^E C 3 SH 0). C O IB -O
(0 -H G nj 0) 3 m JJ *3
o> mono1 'cococD1
ri c mraccw-H
rH O "4H JJ Ol }H 0) iH -H JJ rH'
(0-HOC.Q O'nSnJO
aJ|C-HrHoScc°''I!
' O JJ M S 01 E CO - JJ -O -6 -O -C
'OOl-HQJ JJ CO O O O O
ox (u-H o "e .3 a a a a
JJ OCQi— IMH4-|i4-Jlj-iC4_|
W -U JJ < ft -H -H -H -H -H
42 0) 3* w
\ -r* £J
(0 T3
•H
QJ O
42 C
JJ M
(0 O
JJ 73,
.
-------
03
o
d)
cn
At
CM
O
CJ
EH
&
Q
.
Agency
§
Protectd
States Environmental
Q)
•H
B
20460
Washington, D. C.
CO
rR
UtJ
H
8
1
GUIDELI:
D KEY DEFINITIONS FOR
S
3
F*N
CO
1
cH
8
fa
linone
0
N
rt
ylisothi
4J
CO
U-l
O
CQ
C
O
•H
jj
•H
-1
01
JJ r-l
U 01
01 *O
U-l C
0)
c o
o
a o
jj
•rt ra
•rt -H
01
rH C
01 JJ
• -o o
0 * 1
• OJ J=
JJ
rH
w .33
Q) JJ
JJ 01 01
O o -H
cur under conditions of use.
0
o
jj
o
c
01
01
•§
0)
2
CO
o
fl)
-rt
0)
ns ' •
•rl
O
-------
EPA'S BATCHING OF METHYLISOTHIAZOLINONE (5-Chloro-2-methyI-3(2H)-
isothiazolone and 2-Methyl-3(2H)-isothiazolone) PRODUCTS FOR MEETING ACUTE
TOXICITY DATA REQUIREMENTS FOR REREGISTRATION
In an effort to reduce the time, resources, and number of animals needed to fulfill the acute toxicity
data requirements for reregistration of products containing methylisothiazolinone (approximately
a 3:1 ratio of 5-Chloro-2-methyl-3(2H)-isothiazolone ,and 2-Methyl-3(2H)-isothiazolone
respectively) as the active ingredient, the Agency has batched products which can be considered
similar for purposes of acute toxicity. Factors considered in the sorting process include each
product's active and inert ingredients (identity, percent composition and biological activity), type of
formulation (e.g., emulsifiable concentrate, aerosol, wetfable powder, granular, etc.), and labeling
(e.g., signal word, use classification, precautionary labeling, etc.). Note that the Agency is not
describing batched products as "substantially similar", since some products within a batch may not
be considered chemically similar or have identical use patterns.
Using available information, batching has been accomplished by the process described in the
preceding paragraph. Notwithstanding the batching process, the Agency reserves the right to require,
at any time, acute toxicity data for an individual product, should the need arise.
Registrants of products within a batch may choose to cooperatively generate, submit or cite a single
battery of six acute toxicological studies to represent all the products within that batch. It is the
registrants' option to participate in the process with all other registrants, only some of the other
registrants, or only their own products within a batch, or to generate all the required acute
toxicological studies for each of their own products. If a registrant chooses to generate the data for
a batch, he/she must use one of the products within the batch as the test material. If a registrant
chooses to rely upon previously submitted acute toxicity data, he/she may do so provided that the
data base is complete and valid by today's standards (see acceptance criteria attached), the
formulation tested is considered by EPA to be similar for acute toxicity, and the formulation has not
been significantly altered since submission and acceptance of the acute toxicity data. Regardless of
whether new data are generated or existing data are referenced, registrants must clearly identify the
test material by EPA Registration Number. If more than one Confidential Statement of Formula
(CSF) exists for a product, the registrant must indicate the formulation actually tested by identifying
the corresponding CSF.
In deciding how to meet the product specific data requirements, registrants must follow the
directions given in the Data Call-in (DCI) Notice and its attachments appended to the RED. The DCI
Notice contains two response forms which are to be completed and submitted to the Agency within
90 days of receipt. The first form, "Data Call-in Response," asks whether the registrant will meet
the data requirements for each product. The second form, "Requirements Status and Registrant's
Response," lists the product specific data required for each product, including the standard six acute
toxicity tests. A registrant who wishes to participate in a batch must decide whether he/she will
provide the data or depend on someone else to do so. If a registrant supplies the data to support a
batch of products, he/she must select one of the following options: Developing Data,(Option 1);
Submitting an Existing Study (Option 4); Upgrading an Existing Study (Option 5); or, Citing an
123
-------
Existing Study (Option 6). If a registrant depends on another's data, he/she must choose among: Cost
Sharing (Option 2); Offers to Cost Share (Option 3); or, Citing an Existing Study (Option 6). If a
registrant does not want to participate hi a batch, the choices are Options 1,4,5, or 6. However, a
registrant should know that choosing not to participate in a batch does not preclude other registrants
in the batch from citing his/her studies and offering to cost share (Option 3) those studies.,
Eighty-three (83) products were found which contain methylisothiazolmone (5-Chloro-2-methyl-
3(2H)-isothiazolone and 2-Methyl-3(2H)-isothiazolone) as the active ingredient, plus two (2)
products which contain only 2-Methyl-3(2H)-isothiazolone as the active ingredient. These products
have been placed into eighteen batches hi accordance with the active and inert ingredients and type
of formulation.
Results from studies available to the Agency indicate that products containing (a wide range of
percentages) of methylisothiazolmone as the, active ingredient produce irreversible destruction of
ocular tissue or cornea! involvement/irritation lasting for more than 21 days. Therefore, all products
containing this active ingredient will be classified as Toxicity Category I. However, if the registrant
does not agree with this classification, new studies must be submitted/cited to fulfill the primary eye
irritation data requirement.
Studies assessing skin sensitization are not required, because the existing data for the Technical (SF-
886 Technical industrial Microbicide) indicate that the active ingredients are skin sensitizers, and
therefore, all products (including the End Use Products) would be considered positive for skin
sensitization. However, if the registrant does not agree with this classification, new studies must be
submitted/cited to fulfill the skin sensitization data requirement.
The folio whig summarizes acute data requirements by batch:
• The registrant with the product in Batch 1 must cite/submit all acute data (except for the
primary eye irritation and the skin sensitization data).
• The products in Batch la may be supported by citing/submitting the acute data from Batch
1. Data from EPA Reg. No. 707-256 may not be used to support EPA Reg. No. 707-255.
I. The registrants with products in Batch 2 need to cite/submit all acute data (except for the primary
eye irritation and skin sensitization data) on one of the subject products.
n. The registrants with products hi Batch 3 need to cite/submit all acute data (except for the primary
eye irritation and skin sensitization data) on one of the subject products.
III. The registrants with products in Batch 3a may cite/submit all acute data (except for the primary
eye irritation and skin sensitization data) on one of the subject products. Products in Batch 3a may
also be supported by data from products in Batch 3.
124
-------
IV. The registrants with products in Batch 4 need to cite/submit all acute data (except for the
primary eye irritation and skin sensitization data) on one of the subject products.
-V. The registrants with products in Batch 4a may cite/submit all acute data (except for the primary
eye irritation and skin sensitization data) on one of the subject products. Products in Batch 4a may
be supported by data from products in Batch 4.
VI. The registrants with products in Batch 5 need to cite/submit all acute data (except for the
primary eye irritation and skin sensitization data). •
The registrants with products in Batch 5a may cite/submit all acute data (except for the
primary eye irritation and skin sensitization data) on one of the subject products. Products
. , in Batch 5a may be supported by data from products in Batch 5.
VII. The registrant with the product in Batch 6 needs to cite/submit all acute data (except for the
primary eye irritation and skin sensitization data).
VIII. The registrant with the product in Batch 7 needs to cite/submit all acute data (except for the
primary eye irritation and skin sensitization data). The product in Batch 7 may also be supported
by data from the products in Batch 4. .
IX. The registrants with products in Batch 8 need to cite/submit all acute data (except for the
primary eye irritation and skin sensitization data) on one of the subject products.
X. The registrants with products in Batch 9 need to cite/submit all acute data (except for the primary
eye irritation and skin sensitization data) on one of the subject products.
Xl. The registrant with the product in Batch 10 needs to cite/submit all acute data (except for the
primary eye irritation and skin sensitization data).
XII.The registrants with products in Batch lOa need to cite/submit all acute data (except for the
primary eye irritation and skin sensitization data). EPA Reg. No. 68708-9 may be supported bv data
from EPA Reg. No. 67071-16.
XIII. The registrant with the product in Batch 11 needs to cite/submit all acute data (except for the
primary eye irritation and skin sensitization data).
XIV. The registrants with products in Batch 12 need to cite/submit all acute data (except for the
primary eye irritation and skin sensitization data). EPA Reg. No. 1448-398 may be supported by
data from EPA Reg. No. 1448-397.
XV. The registrant with the product in Batch 13 needs to cite/submit all acute data (except for the
primary eye irritation and skin sensitization data). ;
125
-------
XVI. The Registrant with the product in Batch 14 needs to cite/submit all acute data (except for the
primary eye irritation and skin sensitization data).
NOTE: The technical acute toxicity values included in this document are for informational purposes
only. The data supporting these values may or may not meet the current acceptance criteria.
[Under "% Active Ingredient", the 5-Chloro-2-methyl-3(2H)-isothiazolone is listed as
^5-Chloro-2-methyl", and the 2-Methyl-3(2H)-isothiazolone is listed as "2-Methyl".]
Batch
1
EPA Reg. No.
707-234
% Active Ingredient
70.1% 5-Chloro-2-methyl
26.0% 2-Methyl
Formulation Type
Liquid
Batch
la
EPA Reg. No.
707-255
707-256
% Active Ingredient
93.8% 2-Methyl
50.0% 2-Methyl
Formulation Type
Liquid
Liquid
1 , I , , , , ' " • ' , i ; ' ^ , ' , , , „ , , ' ' t
Batch
2
EPA Reg. No.
707-128
707-129
707-130
707-132
707-194
707-217
6836-238
6836-239
6836-240
49403-24
67071-5
67071-9
% Active Ingredient
10.4% 5-Chloro-2-methyl
3. 7% 2-Methyl
10.4% 5-Chloro-2-methyl
3.7% 2-Methyl
10.4% 5-Chloro-2-methyl
3.7% 2-Methyl
10.4% 5-Chloro-2-methyl
3. 7% 2-Methyl
10.4% 5-Chloro-2-methyl
3. 7% 2-Methyl
10.4% 5-Chloro-2-methyl
3.7% 2-Methyl
10.8% 5-Chloro-2-methyl
3.83% 2-Methyl
10.8% 5-Chloro-2-methyl
3.83% 2-Methyl
10.8% 5-Chloro-2-methyl
3.83% 2-Methyl
8.6% 5-Chloro-2-methyl
2.6% 2-Methyl
10.2% 5-Chloro-2-methyl
4.0% 2-Methyl
10.2% 5-Chloro-2-methyl
4.0%2-Methyl
Formulation Type
Liquid
Liquid
Liquid
Liquid,
Liquid
Liquid
Liquid
Liquid
Liquid
Liquid
Liquid
Liquid
126
-------
Batch
3
EPA Reg. No.
707-220
1706-170
6836-257
45017-42
45017-44
% Active Ingredient
2.69% 5-Chloro-2-methyl
0,81% 2-Methyl
3. 1 1% 5-Chloro-2-methyl
0.94% 2-Methyl
,3:69%5-Chloro-2-metiiyl
1.31% 2-Methyl
2.8% 5-Chloro-2-methyl
1.0% 2-Methyl
2.30% 5-Chloro-2-methyl
. 0.70% 2-Methyl
Formulation Type
Liquid
Liquid
Liquid
Liquid
Liquid
Batch
3a
EPA Reg. No.
, 707-171
10707-44
% Active Ingredient
4.3% 5-Chloro-2-methyl
1.3% 2-Methyl
5.36% 5-Chloro-2-methyl
1.62% 2-Methyl
Formulation Type
Solid
Solid
Batch
4
EPA Reg. No.
527-105
707-133
"-. '.
707-134
707-196
707-209
707-216
707-219
707-260
1448-348
1553-126
1706-153
1706-158
1706-183
% Active Ingredient
1.15%5-Chloro-2-methyl
0.35% 2-Methyl
1.11% 5-Chloro-2-methyl
0.39% 2-Methyl
1.11% 5-Chloro-2-methyl
0.39% 2-Methyl
1.11% 5-Chloro-2-methyl
0.39% 2-Methyl
1.1 1% 5-Chloro-2-methyl
0.39% 2-Methyl
1.11% 5rChloro-2-methyl
0.39% 2-Methyl
1.11% 5-Chloro-2-methyl
0.39% 2-Methyl
1.1 1% 5-Chloro-2-methyl
.0.39% 2-Methyl
1 . 1 5% 5-Chloro-2-methyl
0.35% 2-Methyl
1.15% 5-Chloro-2-methyl
0.35% 2-Methyl
1 .15% 5^Chloro-2-methyl
0.35% 2-Methyl
1.15% 5-Chloro-2-methyl
0.35% 2-Methyl
1.12% 5-Chloro-2-methyl
0.40% 2-Methyl
Formulation Type
Liquid
Liquid
Liquid
Liquid
Liquid
Liquid
Liquid
Liquid
Liquid
Liquid
Liquid
Liquid
Liquid
127
-------
Batch
4
EPA Reg. No.
1757-67
1757-79
3635-271
3876-143
3876-156
3931-7
6836-258
6836-259
' 8540-23
8591-34
9386-38
10445-66
10445-69
10707-38
11529-12
15300-24
33355-12
45017-34
48301-9
49403-25
67071-01
67071-08
% Active Ingredient
1.15% 5-Chloro-2-methyl
0.35% 2-Methyl
1.15% 5-Chloro-2-methyl
0.35% 2-Methyl
1.15% 5-Chloro-2-methyl
0.35% 2-Methyl
1.15% 5-Chloro-2-methyl
0.35% 2-Methyl
1.15% 5-Chloro-2-methyl
0.35% 2-Methyl
1.11% 5-Chloro-2-methyl
0.39% 2-Methyl
1.11% 5-Chloro-2-methyl
0.39% 2-Methyl
1.1 1% 5-Chloro-2-methyl
' . 0.39% 2-Methyl
1.15% 5-Chloro-2-methyl
0.35% 2-Methyl
1.15% 5-Chloro-2-methyl
0.35% 2-Methyl
1.11% 5-Chloro-2-methyl
0.39% 2-Methyl
1 . 1 5% 5-Chloro-2-methyl
0.35% 2-Methyl
1.15% 5-Chloro-2-methyl
0.35% 2-Methyl
1.15% 5-Chloro-2-methyl
0.35% 2-Methyl
1 . 1 5% 5-Chloro-2-methyl
0.35% 2-Methyl
1 . 1 5% 5-Chloro-2-methyl
0.35% 2-Methyl
1.15% 5-Chloro-2-methyl
0.35% 2-Methyl
1.15% 5-Chloro-2-methyl
0.35% 2-Methyl
1.15% 5-Chloro-2-methyl
0.35% 2-Methyl
1.15% 5-Chloro-2-methyl
0.35% 2-Methyl
1.1% 5-Chloro-2-methyl
0.4% 2-Methyl
1.1% 5-Chloro-2-methyl
0.4% 2-Methyl
Formulation Type
Liquid
Liquid
Liquid
Liquid
Liquid
Liquid
Liquid
Liquid
Liquid
Liquid
Liquid
Liquid
Liquid
Liquid
Liquid
Liquid
Liquid
Liquid
Liquid
Liquid
Liquid
Liquid
128
-------
Batch
4
EPA Reg. No.
67071-10
67071-11
67071-12
67071-13
67071-14
68329-17
68708-1
% Active. Ingredient
1.11% 5rChloro-2-methyl
0.44% 2-Methyl'
1.1 1% 5-Chloro-2-methyl ,
0.44% 2-Methyl
1.1 1% 5-Chloro-2-methyl
0.44% 2-Methyl '
1 . 1 1 % 5-Chloro-2-methyl
0.44% 2-Methyl
1.11% 5-Chloro-2-methy 1
, 0.44% 2-Methyl
.1.11% 5-Chloro-2-methyl
0.39% 2-Methyl
1.15% 5-Chloro-2-methyl
0.35% 2-Methyl
Formulation Type
Liquid
Liquid
Liquid
Liquid
Liquid
Liquid
Liquid
Batch ,
4a
EPA Reg. No.
707-166
707-218
6836-241
% Active Ingredient
1.11% 5-Chloro-2-methyl
0.39% 2-Methyl
1.11% 5-Chloro-2-methyl
0.39% 2-Methyl
1 . 1 8% 5-Chloro-2-methyl
. , 0.40% 2-Methyl
Formulation Type
Liquid
Liquid
Liquid
Batch
5
EPA Reg. No.
707-168,
10707-13
% Active Ingredient ,
1.15% 5-Chloro-2-methyl
• 0.35%2-MethyI
1.15% 5-Chloro-2-methyl
.0.35% 2-Methyl
Formulation Type
Liquid
Liquid
Batch
5a
EPA Reg. No.
707-167.
101-169
% Active Ingredient
1.15% 5-Chloro-2-methyl
0.35% 2-Methyl
1.15% 5-Chloro-2-methyl
> .0.35% 2-Methyl .
Formulation Type
Liquid '
Liquid
Batch
6
EPA Reg. No.
707T198
% Active Ingredient
1 J 1 1 % 5-Chloro-2-methyl
0.39% 2-Methyl .
Formulation Type
Liquid
129
-------
Batch
7
EPA Reg. No.
1757-74
% Active Ingredient
0.575% 5-Chloro-2-methyl
0.175%2-Methyl
" Formulation Type
Liquid
Batch
8,
EPA Reg. No.
48301-16
69838-1
% Active Ingredient
0.7% 5-Chloro-2-methyl
0.2%2-Methyl
0.8% 5-Chloro-2-methyl
0.3% 2-Methyl
Formulation Type
Liquid
Liquid
Batch
9
EPA Reg. No.
60061-78
60061-93
% Active Ingredient
0.06% 5-Chloro-2-methyl
0.02% 2-Methyl
64.34% Didecyl Dimethyl Ammonium Chloride
7.55% 3-Iodo-2-Pfopynyl Butyl Carbamate
0.06% 5-Chloro-2-methyl
0.02% 2-Methyl
31.94% Didecyl Dimethyl Ammonium Chloride
3.75% 3-Iodo-2-Propynyl Butyl Carbamate
Formulation Type
Liquid
Liquid
Batch
10
EPA Reg. No.
3876-151
% Active Ingredient
1.6% 5-Chloro-2-methyl
0.5% 2-Methyl
5.3%2-Bromo-2-nitropropane-l,3-diol
Formulation Type
Liquid
Batch
lOa
EPA Reg. No.
67071-16
68708-9
% Active Ingredient
0.84% 5-Chloro-2-methyl
0.33% 2-Methyl
' 8.80% 2-Bromo-2-nitropropane-l,3-diol
0.28% 5-Chloro-2-methyl
0.10% 2-Methyl
8.80%2-Bromo-2-nitropropane-l,3-diol
Formulation Type
Liquid
Liquid
Batch
11
EPA Reg. No.
1448-396
% Active Ingredient
1.04% 5-Chloro-2-methyl
0.37% 2-Methyl
1 .0% 2-Bromo-2-nitropropane- 1 ,3-diol
12.0% Poly[oxyethylene (dimethyliminio)
ethylene(dimethyliminio)ethylene] dichloride
Formulation Type
Liquid
130
-------
Batch
EPA Reg. No.
% Active Ingredient
Formulation Type
12
1448-397
1448-398
1.04% 5-Chloro-2-methyl
- 0.37%2-Methyl
12.0% Polyfoxyethylene (dimethyliminio)
ethylene(dimethyliminio)ethylene]dichloride
0.52% 5-Chloro-2-methyl
0.18%2-Methyl
6.0% Polyfoxyethylene (dimethyliminio)
ethylene(dimethyliminio)ethylene] dichloride
, Liquid
Liquid
Batch
13
EPA Reg. No.
3876-157
% Active Ingredient .
1.41% 5-Chloro-2-methyl
0.47%2-Methyl
7.5% Glutaraldehyde
Formulation Type
Liquid
, Batch
14
EPA Reg. No.
10445-89
% Active Ingredient
0.059% 5-Chloro-2-methyl
0.018%2-Methyl
23. 725% 1 ,2-dibromo-2,4-dicyanobutane
Formulation Type
Liquid
131
-------
Cost Share, Data Compensation Forms, Confidential Statement of Formula Form and
Instructions
The Confidential Statement of Formula (CSF) Form 8570-4 must be used. Two legible, signed
copies of the form are required. Following are basic instructions:
a. All the blocks on the form must be filled in and answered completely.
b. If any block is not applicable, mark it N/A.
c. The CSF must be signed, dated and the telephone number of the responsible party
niust be provided.
d. All applicable information which is on the product specific data submission must
also be reported on the CSF.
I
e. All weights reported under item 7 must be in pounds per gallon for liquids and
pounds per cubic feet for solids.
f. Flashpoint must be in degrees Fahrenheit and flame extension in inches.
n,' '• i n'?!' ', . . : , 'i .',,:• • ,. ' • . ' ' ' , /•, • |
g. For all active ingredients, the EPA Registration Numbers for the currently registered
source products must be reported under column 12.
h. The Chemical Abstracts Service (CAS) Numbers for all actives and inerts "and all
common names for the trade names must be reported.
I. for the active ingredients, the percent purity of the source products must be reported
under column 10 and must be exactly the same as on the source product's label.
j. All the weights in columns 13 .a. and 13 .b. must be in pounds, kilograms, or grams.
In no case will volumes be accepted. Do not mix English and metric system units
(i.e., pounds and kilograms).
k. All the items under column 13.b. must total 100 percent.
1. ' All items under columns 14.a. and 14.b. for the active ingredients must represent
pure active form.
" " ' . • ' .' !
m. The upper and lower certified limits for aT-1 active and inert ingredients must follow
the 40 CFR 158.175 instructions. An explanation must be provided if the proposed
limits are different than standard certified limits.
n.
When new CSFs are submitted and approved, all previously submitted CSFs become
obsolete for that specific formulation.
132
-------
^j)
i
i
S
m
5
i
<
.
s
j?
a
6
m
2
O
j
O
u_
5?
0
*.
O
•
e
a
|
S
j?
9
5
,
1(0
to.
;C
O
w
c
.5
5
3
I
O
V3
°
_
.1 a
a E
e i?
o S
Urn O
« C 1
o c i
s 1
CD <|
DD
-
a
3
2 i
1? "SI
!
S
«
i
a
u
-gj
'o
2
1
•Q
c
(0
at
•
H
o
o
CO
i
i
I
•
i
j|
f 1
-""
„ \
hi
•o 5^
l|i
2 |
N
ij
. Each Comf
in Formula!
Amount
*~ to
5
at
o»
(T
-------
134
-------
United States Environmental Protection Agency
Washington, D.C. 20460
Certification of Offer to Cost
Share in the Development of Data
Form Approved
OMB No. 2070-0106,
2070-0057
Approval Expires
3-31-99
Public reporting burden for this collection of information is estimated to average 15 minutes per response, including
time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and
completing and reviewing the collection of information. Send comments regarding the burden estimate or any other
aspect of this collection of information, including suggestions for reducing this burden to, Chief Information Policy
Branch, PM-233, U.S. Environmental Protection Agency, 401 M St., S.W., Washington, DC 20460; and to the Office of
Management and Budget, Paperwork Reduction Project (2070-0106), Washington, DC 20503.
Please fill in blanks below:
I Certify that:
Company Number ,
\
EPA Reg. No.
My company is willing to develop and submit the data required by EPA under the authority of the Federal
Insecticide, Fungicide and Rodenticide Act (FIFRA), if necessary. However my company would prefer to
enter into an agreement with one or more registrants to develop jointly or share in the cost of develooina
data.
My firm has offered in writing to enter into such an agreement. That offer was irrevocable and included an
an offer to be bound by arbitration decision under section 3(c)(2)(B)(iii) of FIFRA if final agreement on all
terms could not be reached otherwise. This offer was made to the following firms on the following
date(s):
NameofFirm(s)
Date of Offer
Certification:
certify that I am duly authorized to represent the company named above, and that the statements that I have made on
this form and all attachments therein are true, accurate, and complete. I acknowledge that any knowingly false or
misleading statement may be punishable by fine or imprisonment or both under applicable law.
Name and Title (Please
Date
i Form 8570-32 .(5/91) Replaces EPA form 8580 which is obselete
135
-------
136
-------
Form Approved OMB No. 2070-0060
UNITED STATES ENVIRONMENTAL PROTECTION AGENCY
401 M Street, S.W.
WASHINGTON, D.C. 20460
Paperwork Reduction Act Notice: The public reporting burden for this collection of information is estimated to average 1.25 hours per response for
registration and 0.25 hours per response for reregistration arid special review activities, including time for reading the instructions and completinq the
necessary forms. Send comments regarding burden estimate or any other aspect of this collection of information, including suggestions for reducing the
burden to: Director, OPPE Information Management Division (2137), U.S. Environmental Protection Agency, 401 M Street, S W Washington DC 20460
Do not send the completed form to this address. ' '
Certification with Respect to Citation of Data
Applicant's/Registrant's Name, Address, and Telephone Number
Active Ingredients) and/or representative test compound(s)
General Use Pattern(s) (list all those claimed for this product using 40 CFR Part 1 58)
EPA Registration Number/File Symbol
Date
Product Name
NOTE: If your product is a 100% repackaging of another purchased EPA-registered product labeled for all the same uses on your label you do not need to
submit this form. You must submit the Formulator's Exemption Statement (EPA Form 8570-27). '
Dl am responding to a Data-Call-in Notice, and have included with this form a list of companies sent offers of compensation (the Data Matrix form
should be used for this purpose). . ,
SECTION I: METHOD OF DATA SUPPORT (Check one method only)
I am using the cite-all method of support, and have included with this
form a list of companies sent offers of compensation (the Data Matrix
form should be used for this purpose).
D
I am using the selective method of support (or cite-all option
under the selective method), and have included with this form a
completed list of data requirements (the Data Matrix form must
be used).
SECTION II: GENERAL OFFER TO PAY
[Required if using the cite-all method or when using the cite-all option under the selective method to satisfy one or more data requirements]
J I hereby offer and agree to pay compensation, to other persons, with regard to the approval of this application, to the extent required by FIFRA.
SECTION III: CERTIFICATION
.. ' 9®^that tnis aPP|lcat'°n for registration, this form for reregistration, or this Data-Call-in response is supported by all data submitted or cited in
the application for registration, the form for reregistration, or the Data-Call-in response. In addition, if the cite-all option or cite-all option under the selective
method is indicated in Section I, this application is supported by all data in the Agency's files that (1) concern the properties or effects of this product or an
dentical or substantially similar product, or one or more of the ingredients in this product; and (2) is a type of data that would be required to be submitted
under the data requirements in effect on the date of approval of this application if the application sought the initial registration of a product of identical or
similar composition and uses. t
- ^
^ • ., .i06^trtat for.eacn exclusive use study cited in support of this registration or reregistration, that I am the original data submitter .or that I have
obtained the wntten permission of the original data submitter to cite that study.
I certify that for each study cited in support of this registration or reregistration that is not an exclusive use study, either (a) I am the original data
submitter; (D) I have obtained the permission of the original data submitter to use the study in support of this application; (c) all periods of eligibility for
compensation have expired for the study; (d) the study is in the public literature; or (e) I have notified in writing the company that submitted the study and
lave offered (I) to pay compensation to the extent required by sections 3(c)(1)(F) and/or 3(c)(2)(B) of FIFRA; and (if) to commence negotiations to determin.
he amount and terms of compensation, if any, to be paid for the use of the study.
I certify that in all instances where an offer of compensation is required, copies of all offers to. pay compensation and evidence of their delivery in
accordance with sections 3(c)(1 )(F) and/or 3(c)(2)(B) of FIFRA are available and will be submitted to the Agency upon request Should I fail to produce sucW
evidence to the Agency upon request, I understand that the Agency may initiate action to deny, cancel or suspend the registration of my product in' I
conformity with FIFRA. ' II
I certify that the statements I have made on this form and all attachments to it are true, accurate, and complete. I acknowledge that any
knowingly false or misleading statement may be punishable by fine or imprisonment or both under applicable law.
Signature
Date
Typed or Printed Name and Title
Form 8570-34 (9-97) Electronic and Paper versions available. Submit only Paper version.
-------
-------
-------
-------
o
(O
§ -
o
o
CM
6
2
GO
O
fl)
§
Q.
CL
**•
C
O
u_
O
Z
UJ
O
^
Z
o
t-
o
UJ o
^™ to
-J CO U
' ^* ® •»
SEP.
Q£ S
•^ ^f ^^
Z << '
UJ §
CO >
IJ
CO
Q
UJ
Z
®
Jo
._ o O
•£:= c£
en o o
to o *i
c: to O)
o~ .C
m "*~ ^5
fc- CO
If -
. to to ^
~J ® 5*
° a5 CO
s^«"
O c* 2J
T3 CO yy
CO O ^
CO CO
S^O
^ '-^ "^"
° flj >»
r- y
O CD {])
'•gf ro
o c1^
"o o
c o>^*
S £ 15
S J2 c
£ c CD
g.E c
CO Q 2
5 o'>
0 -o C
J= c UJ
CM co tyj
o . -j
|||
CO ^j
•28 §
•§s«
lis
"Jo £ g
D> C /
».= §
C
.2 "5. g
to E co
P o s
£ o "^
•§"§ .2
111
o — -S
&5 uj
8 = 2:
.CO CD O
f ra|
*" S ®
lie
-^ o £
O) Q) (D
ill
2 o>-°
CD .£ o> to
"- "o -c co
o = T*. a)
15! g-o
5 — "o t3
"• „,- 3 CO
.c :§:'£•—
*~ -^ 0 ^
Jto CJ *^ O
Q CO CO "*•*
? CD J ^
5 | 0^
<"55 §£
C '5 CO TJ ,
itfl
o
•£-.§ =Q
CD '5) £ CD
X
fg
1-
<
s
<
Q
<
]
I
Q.
"5
s.
-
co
=
LL.
C
O)
CD
CC
D.
LL
CD
§
3
•o
g
EL
CO
£
•o
•o
*£.
CO
£
Z
(/f
1
"to
o>
Q>
Q£
To
CO
U
I
I
£
D)
C
<
"!
§
J
o
£
|
cc
1
; E
a
Q
CC
I
CO
•z.
•Q
CO
ID
.^
CD
O
CD
E
3
"Z.
s
I
.2
0
Guideline
'-'
£
ro
Q
CO
_
c
k.
*-
—
>,
U
CD
O)
^
cf
o
a
>
CD
O.
CD
O
1
CO
1
JO
"co
CO
CO
c
o
2
CD
CD
Q.
CO
Q.
TJ
CO
O
P
G
S
u
.•-••.
I
n
v^
tj
3
n
o
5
L.
£
II
-------
INSTRUCTIONS FOR DATA MATRIX
INSTRUCTIONS: Identify all data submitted or cited and all submitters from whom permission has been received or to whom offers to pay
have begn sent by entering sufficient information in the attached matrix (photocopy and attach additional pages as necessary). Complete
Alt columns; omission of essential information will delay approval of the registration/reregistration. On each page enter the date,
Applicant's/Registrant's name, EPA Registration Number or application file symbol of the product, ingredient, page number, and total |
number of pages.
The Data Compensation Form entitled "Certification with Respect to Citation of Data" and the Data Matrix will be publicly available, except
for the Guideline Reference Number, Guideline Study Name, and MRID Number columns after the registration/reregistration of this product
has been granted or once this form is received in response to a Data-Call-in Notice. However, the information in the Guideline Reference
Number, Guideline Study Name, and MRID Number columns is available through the Freedom of Information Act in association with the |
EPA Registration Number.
Ingredient: Identify the active ingredients) in this product for which data are cited. The active ingredients) are to be identified by entering
the chemical name and the CAS registry number. Begin a new page for each separate active ingredient for which data are cited. If bridging
data from a related chemical or representative test compound are cited, enter the identity of that chemical/representative test compound
including the EPA Registration Number/File Symbol if appropriate.
If the cite-all methocJ is used for all data supporting this particular ingredient, enter "CITE-ALL" in the Guideline Reference Number I
Column and leave the Guideline Study Name column blank. If the cite-all method is used for a particular Guideline Reference Number enter
"CITE-ALL" in the MRID Number column on the line for that Guideline Reference Number. In either case, enter all submitters to whom
offers to pay have been sent on subsequent lines. [Note: if the selective method of support is used and written authorization (letter of
permission) is provided, the individual Guideline Reference Number, Guideline Study Name, and MRID Number columns must still be
completed.] Otherwise:
Guideline Reference Number: Enter on separate lines in numerical order the Guideline Reference Numbers from 40 CFR Part 158 for |
all studies cited to support the registration/reregistration for this ingredient.
Guideline Study Name: For each Guideline Reference Number cited, enter the corresponding Guideline Study Name.
MRID Number: For each individual study cited in support of a Guideline Reference Number and Guideline Study Name, enter the Master I
Record Identification (MRID) Number listed in the Pesticide Document Management System (PDMS). Enter only one MRID Number on I
each line. Note that more than one MRID Number may be required per Guideline Reference Number. Note: Occasionally a study required
to maintain a registration/reregistration is not associated with a Guideline Reference Number and Guideline Study Name. In such case,
e,nter the MRID Numbers) for the study(ies).
Submitfen Using the mosl recent Data Submitters List, identify the Original Data Submitter with their current address for each study cited.
The EPA assigned company number or other abbreviation may be used. Clearly explain any variations (alternate addresses, data owners
riot on the Data Submitters List, etc.) in footnotes to this table.
Status; Enter one of the following codes for each study cited, as appropriate:
OWN: I am the Original Data Submitter for this study.
EXC: I have obtained written permission of the Original Data Submitter to cite this exclusive-use study in support of this
application.
I have obtained the permission of the Original Data Submitter to use this study in support of this application.
The study was submitted more than 1 5 years ago and all periods of compensation have expired.
The study is in the public literature.
I have notified in writing the Original Data Submitter or, if the cite-all method is used, all companies listed in the most
current Data Submitters List for this ingredient, and have offered (a) to pay compensation in accordance with FIFRA
sections 3(c)(1)(F) and/or 3(c)(2)(B), and (b) to commence negotiations to determine the amount and terms of
compensation, if any, to be paid for the use of the study(ies).
' ;• " if*:- •• ,:< •• • ' ' -. ...... "; ', ''" ',-,;;» •;!':. .,'.-.• . , .'} ;..'"- i . ..: .•}.•''.,. } •> ' • .'''",'
This Guideline data requirement is a data gap as defined in 40 CFR sections 152.83(a) and 152.96.
I am taking the formulator's exemption for this ingredient only. Other columns of this line should be marked "NA".
However, if this product is to be registered/reregistered for additional uses for which the purchased EPA registered
ingredient is not supported, additional data must be submitted or cited here to support those uses.
If additional explanation is heeded, enter a footnote number in this column and attach the corresponding explanation.
PER:
OLD:
PL:
PAY:
GAP:
FOR:
142
-------
United States Environmental Protection Agency
Washington, DC 20460
CERTIFICATION WITH RESPECT TO
DATA COMPENSATION REQUIREMENTS
Form Approved
OMB No. 2070-0107,
2070-0057
Approval Expires
3-31-99
Public reporting burden for this collection of information is estimated to average 15 minutes per response, including time for .
reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the
collection of information. Send comments regarding the burden estimate or any other aspect of this collection of information,
including suggestions for reducing this burden to, Chief, Regulatory Information Division, Mail Code 2137, U.S. Environmental Protection
Agency, 401 M ;St, S.W., Washington, DC 20460; and to the Office of Management and Budget, Paperwork Reduction Project
(2070-0106), Washington, DC 20503. ,• ' .
Please fill in blanks below.
Company Name , •
Product Name ,
Company Number
EPA Reg. No.
I Certify that:
1. For each study cited in support of registration or reregistration under the Federal Insecticide, Fungicide and Rodenticide Act
(FIFRA) that is an exclusive use study, I am the original data submitter, or I have obtained the written permission of the original
data submitter to cite that study.
2. That for each study cited in support of registration or reregistration under FIFRA that is NOT an exclusive use study, I am the
original data submitter, or I have obtained the written permission of the original data submitter, Or I have notified in writing the
company(ies) that submitted data I have cited and have offered to: (a) Pay compensation for those data in accordance with sections
3(c)(l)(F) and 3(c)(2)(D) of FIFRA; and (b) Commence negotiation to determine which data are subject to the compensation
requirement of FIFRA and the amount of compensation due, if any. The companies I have notified are: (check one)
[ ] The companies who have submitted the studies listed on the back of this form or attached sheets, or indicated on the attached "Requirements
Status and Registrants'Response Form,"
3. That I have previously complied with section 3(c)(l)(F) of FIFRA for the studies I have cited in support of registration or reregistration
under FIFRA. .
Signature
Date
Name and Title (Please Type or Print)'
GENERAL OFFER TO PAY: I hereby offer and agree to pay compensation to other persons, with regard to the registration or
reregistration of my products, to the extent required by FIFRA section 3(c)(l)(F) and 3(c)(2)(D).
Signature •
Date
Name and Title (Please Type or Print)
A Form 8570-31 (4-96)
143
-------
List of Available Related Documents
The following is a list of available documents for methylisothiazolinone that my further assist
you in responding to this Reregistration Eligibility Decision document. These documents may be
obtained by the following methods:
;«rf. J . , V, . . . .,,... ,....,'.
i 'I "* ' '
Electronic
File format: Portable Document Format (.PDF) requires Adobe® Acrobat or compatible reader.
Electronic copies can be downloaded from the Pesticide Special Review and
Reregistration Information System at 703-308-7224. They also are available on the
Internet using WWW (World Wide Web) on WWW.EPA.GOV., or contact Venus
Eagle at (703)-308-8045.
1. PRNotice86-5.
2. PR Notice 91-2 (pertauis to the Label Ingredient Statement).
3. A full copy of this RED document.
4. A copy of the fact sheet for methylisothiazolinone.
The following documents are part of the Administrative Record for methylisothiazolinone
and may included in the EPA's Office of Pesticide Programs Public Docket. Copies of these
documents are not available electronically, but may be obtained by contacting the person listed on
the Chemical Status Sheet.
1. Health and Environmental Effects Science Chapters.
2. Detailed Label Usage Information System (LUIS) Report.
The following Agency reference documents are not available electronically, but may be
obtained by contacting the person listed on the Chemical Status Sheet of this RED document.
1. The Label Review Manual.
2. EPA Acceptance Criteria.
144
-------